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Abstract 
________________________________________________________________ 
Introduction: Doxorubicin (DOX) is an effective and widely used chemotherapeutic agent. 
However, its toxicity on healthy tissue limits its usage. DOX is known to induce damage 
mainly via oxidative stress which stimulates oxidative damage and apoptosis either 
intrinsically or extrinsically. While literature has primarily focused on the side effects of DOX 
on the myocardium, very little attention has been paid to the potential toxic effects of DOX on 
peripheral organs such as the liver which metabolises drugs and various toxins. Ghrelin is a 
hormone naturally found in the body which has been found to possess some beneficial 
properties that could protect the liver against DOX toxicity. Up until now, the therapeutic role 
of ghrelin in a chronic model of DOX toxicity has not been evaluated. Therefore, this study 
aimed to evaluate the effects of DOX on the liver and whether the use of ghrelin in this 
context will confer protection. 
Methods: Four week old male Sprague-Dawley rats were randomly divided into four 
experimental groups: vehicle (saline), DOX (2.5 mg/kg/week), ghrelin (300 µg/kg/wk) and 
DOX+Ghrelin (both treatment regimens). Treatment was administered through intraperitoneal 
(i.p) injections for eight weeks where body weight and food consumption was monitored. One 
week after the last injection, the rats were sacrificed and the liver was harvested for 
histological and molecular analysis. Blood, which was separated into serum and plasma was 
also collected to evaluate liver function. Histological staining included Haematoxylin and 
Eosin (H&E), Masson’s Trichome, Reticulin and Oil red O, while molecular experiments 
included oxidative stress analysis, apoptotic and autophagic activity as well as endoplasmic 
reticulum (ER stress). 
Results: Terminal body weights were recorded per week and it was evident by the fourth 
week that the DOX treated animals (228.30 ± 7.09 g, p < 0.001) were not gaining as much 
weight as the vehicle treated animals (285.50 ± 19.24 g). This lack of weight gain was 
maintained until the end of the treatment protocol and coincided with reduced food 
consumption. Ghrelin significantly increased food consumption in the DOX+ghrelin group 
(159.20 g ± 9.43 g, p < 0.05) versus the DOX group (128.50 g ± 7.27), however this effect 
was not reflected in the body weight measurements of this group. Interestingly, DOX induced 
the fusion of liver lobes and this was prevented in the presence of ghrelin. While a normal rat 
liver and those that were treated with ghrelin alone displayed seven lobes, DOX treated 
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animals presented with an average of four lobes and the combination group, an average of six 
lobes. This fusion did not affect survival, liver function or oxidative stress parameters. 
Although autophagic activity was maintained in all treatment groups, DOX+ghrelin prevented 
caspase-3 cleavage and permitted binding immunoglobin protein (BiP) and activating 
transcription factor 4 (ATF4) protein expression. 
Discussion & Conclusion: This study demonstrated that the liver is a robust organ that can 
withstand a great deal of stress and toxicity as weekly administration of DOX did not induce 
severe liver damage. Due to this organs regenerative capabilities, it is highly likely that DOX 
induced early damage of which the liver was able to recover from. While liver morphology 
was altered by DOX, structural parameters measured and function tests remained unchanged. 
No adverse oxidative damage was observed, nor was there any variation in the anti-oxidant 
status of this tissue. Molecularly, ghrelin reduced apoptosis and elevated autophagy. 
Therefore, while ghrelin’s protective effects were mainly observed as a result of its orexigenic 
properties, its effect against DOX on the liver requires further investigation. 
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Chapter 1 
Literature review 
1. The liver
1.1 Anatomy and blood supply 
The liver accounts for ±1.5 - 2.5% of lean body mass and compared to the skin, it is regarded as 
the second largest organ present in the human body (Mitra & Metcalf, 2009). The human liver is 
situated in the abdominal cavity in the right 
upper quadrant, below the right hemi-
diaphragm. While the human liver consists 
of a right and a left lobe, the livers of 
rodents have four lobes (Abdel-Misih & 
Bloomston, 2010). Their livers are divided 
into the median, right, left and caudate 
lobes, with all lobes except the left lobe 
being further divided into two parts. This 
gives the appearance that mice and rats 
have seven to eight liver lobes (Malarkey et 
al., 2005). The liver is protected by the rib 
cage and maintains its position through 
avascular ligaments, which stretch from the 
Glisson capsule, a layer of connective 
tissue covering the liver, to other organs 
that surround the liver including the 
stomach, duodenum and diaphragm 
(Abdel-Misih & Bloomston, 2010). 
The liver is a vascular organ and receives a significant amount of blood supply. At rest, it 
receives up to 25% of cardiac output, more than any other organ (Abdel-Misih & Bloomston, 
2010; Campbell, 2006a). In addition, the liver also receives blood from two chief vascular 
systems, the hepatic artery and the hepatic portal vein (Fig.1.1) (Malarkey et al., 2005). Arterial 
Figure 1.1: Liver blood supply within the human 
body. The hepatic artery brings blood borne 
metabolites and the bulk of oxygenated blood to the 
liver. While the stomach and intestinal veins 
converge to form the hepatic portal vein which brings 
venous blood to the liver. (Adapted from Sherwood, 
2013). 
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blood rich in oxygen (O2) and blood borne metabolites are transported to the liver by the hepatic 
artery, while venous blood containing the bulk of nutrients is brought from the digestive tract via 
the hepatic portal system (Sherwood, 2013; Abdel-Misih & Bloomston, 2010). The latter is a 
complex vascular connection between the digestive tract and the liver, where the stomach and 
intestinal veins meet to form the hepatic portal vein. The hepatic portal vein and the hepatic 
artery extend into the liver and branches into a capillary network that runs through the sinusoids 
between hepatocytes, which are the main cell type found in the liver. This allows for the 
exchange of metabolites between the blood and hepatocytes, and the blood then drains into the 
central hepatic venule. Branches of this hepatic venule merge to form the hepatic vein, where 
blood leaves the liver to enter the inferior vena cava (Sherwood, 2013). From here, the liver 
parenchyma are responsible for the digestion and metabolism of nutrients and toxins, as well as 
the production of different proteins.  
1.2 Hepatic tissue cell types 
Considering that the liver is the second largest organ in the body, it is surprising that there are 
very few specializations amid the cells present in this organ. Cells found within the liver include 
the hepatocytes, sinusoidal epithelial cells, biliary epithelium, Kupffer cells and hepatic stellate 
cells (also known as pericytes), which can transform into myofibroblast-like cells (Young et al., 
2013; Pellicoro et al., 2014). Hepatocytes are the most abundant comprising approximately 60% 
of total cells, and constituting ±80% of the liver volume. They are responsible for the execution 
of metabolic and secretory functions (Sherwood, 2013; Gebhardt, 1992). Hepatocytes are 
characterized by their polyhedral shape containing circular nuclei, and are considered as the 
workhorses of the liver (Young et al., 2013). It is for this reason that they contain an abundance 
of smooth and rough endoplasmic reticulum (ER) which contributes to ±15% of the total cell 
volume. Furthermore, each hepatocyte contains ±30 lysosomes, ±500 peroxisomes, ±1000 
mitochondria and numerous Golgi complexes, ribosomes and cytoskeletal elements. With age 
however, the amount of hepatocytes decrease, hypertrophy and polyploidy takes place, smooth 
ER and lysosomes enlarge, while mitochondria remain the same. The capability and ability of the 
liver to metabolize drugs also declines with age. The sinusoidal endothelial cells form a barrier 
between hepatocytes and blood where they filter fluids, solutes and particles between the blood 
and the space of Disse. The space of Disse is found between hepatocytes and the endothelial cells 
lining the sinusoids, whereas the biliary epithelium serves as a lining for the canaliculi that 
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transports bile. Kupffer cells are resident macrophages that are derived from circulating 
monocytes where they produce cytokines which mediate inflammation (Malarkey et al., 2005). 
The hepatic stellate cells store vitamin A in lipid droplets and under certain stimuli, they lose 
their perinuclear vitamin A droplets and transform into myofibroblast-like cells that produce 
extracellular matrix to promote fibrosis (Albanis et al., 1975; Pellicoro et al., 2014). These cells 
are thus the major determinants of liver regeneration, fibrogenesis and cirrhosis (Malarkey et al., 
2005).  
1.3 Hepatic lobule and the hepatic acinus 
The functional unit of the liver is known as the hepatic lobule which is arranged in a hexagonal 
structure (Fig.1.2). These hexagonal structures are further assembled into a honeycomb-like 
configuration where the corners of the hexagon contain three major vessels: the hepatic artery, 
the portal vein and the bile duct. Together, these vessels are known as the portal triad where 
branches of the hepatic artery and portal vein transport blood in an opposite direction to the 
branches of the bile duct (Campbell, 2006a; Gebhardt, 1992). On the one hand, the hepatic artery 
and portal vein branches from the portal triad into the lobules and form capillary spaces called 
sinusoids. The sinusoids are outlined by sinusoidal endothelial cells and hepatocytes are arranged 
in a single layer between two sinusoids. This increases the exchange of metabolites and secretory 
products between the blood and the hepatocytes (Sherwood, 2013). Between the hepatocytes and 
the endothelial cells outlining the sinusoids, the space of Disse exists. This space contains 
extracellular fluid, hepatic stellate cells and Kupffer cells attached to endothelial cells that outline 
the sinusoids (Pellicoro et al., 2014). The branching of the hepatic artery and portal vein into 
capillaries that extend through the sinusoids, run to the centre of the lobule where they converge 
to form the central hepatic venule. With this, metabolites are then exchanged between the 
hepatocytes and these capillaries (Young et al., 2013). On the other hand, the bile duct follows a 
different route of entry into the lobule. It diverges into branches known as bile canaliculi that run 
between the hepatocytes. Hepatocytes themselves secrete bile into these branches which is then 
transported into the bile duct located at the portal triad. Both the bile and blood are transported in 
different directions; whereas blood flows from the portal triad towards the central hepatic venule, 
bile travels from the bile canaliculi towards the bile duct and into the portal triad (Campbell, 
2006a). Although the hepatic lobule constitutes the structural unit of the liver, hepatic physiology 
is best presented by a structure termed the hepatic acinus.  
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The hepatic acinus (Fig.1.2) is formed from the parenchyma between the portal triad and the 
central hepatic venule. This area can be divided into three zones: the area closest to the portal 
triad is referred to as the periportal zone and designated as zone one (1), followed by the 
intermediate zone designated as zone two (2) in the middle, and the area around the central 
hepatic venule is the pericentral zone designated as zone three (3) (Hijmans et al., 2013). Zone 1 
receives oxygen rich blood and metabolites as it is the closest to the portal triad, while zone 2 and 
3 receive a poor supply of oxygen and metabolites. This arrangement also means that the cells 
present in zone 1 are the ones that are first exposed to blood borne toxins (Young et al., 2013). 
Figure 1.2: Representation of the hepatic lobule and hepatic acinus and the arrangement of the 
hepatocytes and sinusoids.  (A) Illustration of the hepatic lobule with the portal triad at the corners of the 
hexagonal structure and the central vein in the center. The blue arrows indicate blood flow from the portal 
triad to the central vein and the grey arrow, bile flow from the hepatocytes to the bile duct in the portal 
triad. The hepatic acinus is illustrated by the 3 zones. The zones are indicated as zone 1 closest to the 
portal triad followed by zone 2 and then zone 3 closest to the central vein. (B) Magnification of the 
hepatic lobule, the endothelial cells outline the hepatocytes forming the sinusoids, with the space of Disse 
between the hepatocytes and the endothelial cells. (Adapted from Campbell, 2006a). 
1.4. Functional gradients 
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The hepatocytes in the above mentioned zones differ in composition and enzyme activity. 
Hepatocytes closest to the portal triad traditionally have higher levels of oxygen, glucose-6-
phosphatase activity, peroxisomes, bile acid uptake, urea cycle activity, glycogen synthesis and 
glutathione content. This precedes the amounts found in hepatocytes closest to the central hepatic 
venule (Gebhardt, 1992). During starvation, the hepatocytes closest to the portal triad are first 
depleted of glycogen and restored following feeding. Interestingly, the hepatocytes closest to the 
central hepatic venule specialize in a high content of other enzymes including glutamine 
synthetase, glucokinase, carboxylesterase, and ethanol-inducable cyp 2E. (Hijmans et al., 2013; 
Malarkey et al., 2013). The latter forms part of the Cytochrome P450 (CYP) family of enzymes 
responsible for the metabolism of endogenous and exogenous compounds such as steroids, fatty 
acids, alcohol and a variety of drugs (Cho et al., 2017). Hepatocytes are however not the only cell 
type in the liver that differs based on localization.  
The Kupffer cells found in the periportal zone are larger and have elevated phagocytic activity 
compared to those present in the pericentral zone (Bykov et al., 2002). When blood enters from 
the portal triad, the cells closest to this area are first exposed to metabolites and toxins, and the 
Kupffer cells in this region thus offer the first line of defence (Malarkey et al., 2005: Bykov et 
al., 2002). Overall, the liver is organized into a structure suitable for the digestion and 
metabolism of macronutrients, the production and secretion of proteins and the elimination of 
toxins, in addition to the insults it endures that can affect its growth and mass.  
1.5 Liver regeneration 
Even though hepatocytes are terminally differentiated, they can proliferate in response to 
metabolic demands, surgical resection and chemical or viral insults (Fausto et al., 2000). 
Therefore, hepatocyte regeneration following injury is not dependent on progenitor cells (Zaret & 
Grombe, 2008). Quiescent hepatocytes proliferate and replicate to restore the liver’s functional 
capacity and mass upon stimulation (Fausto et al., 2000). These stimuli include growth factors 
such as hepatocyte growth factor (HGF), epidermal growth factor (EGF) and transforming 
growth factor alpha (TGFα). Hepatocytes also need to be primed by cytokines that include 
interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) before they can respond to growth 
factors. At least four transcription factors are required for the initiation of liver regeneration 
namely, nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), activator protein-
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1 (AP-1), signal transducer and activator of transcription 3 (STAT3) and CCAAT-Enhancer-
Binding Protein β (C/EBPβ) (Fausto, 2000; Fausto et al., 2006). The ratio between liver and body 
mass are the main determinants of growth and not the liver mass in isolation. Optimal liver to 
body mass ratio is reached when the liver performs the amount of metabolic work needed for the 
body to function optimally (Fausto, 2000; Michalopoulos & DeFrances, 1997). 
In conditions where the liver undergoes hyperplasia and/or hypertrophy in response to drug 
treatment, removal of this stimuli results in a loss of liver mass to restore the normal liver to body 
mass ratio (Fausto, 2000). Toxic injury, massive necrosis or carcinogenesis may impair or delay 
hepatic proliferation (Friedman, 2000). Under these conditions, a non-parenchymal cell 
compartment proliferates and develops into mature hepatocytes to restore the lost liver mass. The 
adult liver therefore contains facultative progenitor cells identified as the oval cell population 
(Zaret & Grombe, 2008; Zhang et al., 2009). As the name implies, these cells are oval in shape 
with a dark stained nucleus and scant basophilic cytoplasm found in the lining of biliary ductules 
(Zhang et al., 2009; Friedman, 2000). They can differentiate into either hepatocytes or biliary 
epithelium. However, the oval cell population is not homogenous but rather heterogenous 
comprising of cells with differing precursor capabilities at different stages of maturation (Zaret & 
Grombe, 2008). Interestingly, during the postnatal period of the rat, the amount of liver lobules and 
their size may increase for compensatory growth. When adulthood is reached the liver contains a standard 
number of lobules and is unable to grow more lobules in the event of a proliferative trigger. However, 
they are able to grow hepatocytes and increase the size of the hepatic lobules (Papp et al., 2009). While 
the liver has regenerative capacity, chronic insults may impair this trait and instead result in 
fibrosis.  
1.6 Liver fibrosis 
Fibrosis is the excessive build-up of extracellular matrix (ECM) proteins (eg. Type I collagen) 
and if it persists, cirrhosis ensues (Bataller and Brenner, 2005). While fibrosis is reversible, 
cirrhosis, with rare exceptions is not (Bissel, 1998; Friedman, 2000). Fibrosis becomes clinically 
relevant when dysregulated and excessive scarring occurs in response to chronic and persistent 
injury. Normally, the space of Disse contains a basement membrane-like matrix. This normal 
subendothelial ECM is important for maintaining the differentiated function of all resident liver 
cells. Once the liver becomes fibrotic, there are qualitative and quantitative changes in the 
composition of hepatic ECM. There is 3-5 fold increase in the total content of collagen and non-
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collagenous components accompanied by a change in the type of ECM in the subendothelial 
space from the standard low density basement membrane-like matrix, to the interstitial type 
matrix containing fibril-forming collagens (Friedman, 2000).  
As mentioned previously, the cell type mainly associated with fibrosis is the hepatic stellate cells. 
These cells are activated in response to liver injury which causes them to transform from a 
quiescent state into a proliferative, fibrogenic and contractile myofibroblast state (Albanis et al., 
1975; Pellicoro et al., 2014). The stimuli for activation includes free radicals and leukocytes that 
are recruited to phagocytose dead or apoptotic hepatocytes. The immune cells intensify the 
inflammatory response by secreting pro-inflammatory cytokines (TNF, IL-6, IL-1β) and this 
recruits more T cells to the site of injury. The pro-inflammatory mediators produced by damaged 
cells and immune cells, includes cytokines and growth factors such as platelet-derived growth 
factor (PDGF), connective tissue growth factor (CTGF), transforming growth factor beta (TGFβ), 
all mediate the activation of hepatic stellate cells (Pellicoro et al., 2004). Moreover, 
myofibroblasts are also implicated in the closure of cutaneous wounds. Taken together, the 
contractile function of activated stellate cells during chronic liver injury may disrupt normal 
hepatic morphology by contributing to the distortion of lobular architecture and portal 
hypertension (Bissel, 1998).  
1.7  Metabolism 
1.7.1 Fat digestion 
The stomach and its gastrointestinal juices are unable to metabolize lipids, therefore the liver 
produces bile to aid in the digestion of fats. Bile is an alkaline electrolyte solution containing bile 
salts and pigments which are stored in the gall bladder (Campbell, 2006b). Once dietary lipids 
and amino acids are present within the small intestine, enteroendocrine I cells present in the 
duodenal and jejunal mucosa secrete the hormone cholecystokinin which stimulates contraction 
of the gall bladder and relaxation of the sphincter of Oddi. As a result of this contraction-
relaxation cycle, bile is released into the duodenum and assists the enzyme, pancreatic lipase, in 
fat digestion (Sherwood, 2013; Griifin, 2013). The final products of fat digestion within the small 
intestine are monoglycerides and free fatty acids which are packaged into vesicles called 
chylomicrons. These chylomicrons are transported in to the circulation via lymphatic vessels and 
do not enter the liver.  
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Lipoprotein lipase, situated on a variety of tissues including the liver, is responsible for the 
release of free fatty acids from plasma chylomicrons (Ory, 2007; Camps et al., 1991). Fatty acids 
are the liver’s predominant source of energy and when in circulation, are recruited into the liver 
to undergo beta-oxidation within the mitochondria of hepatocytes (Campbell, 2006b). The liver 
also stores lipids in the form of triglycerides, which are fatty acids attached to a glycerol group 
via esterification. If these triglycerides are not stored in the liver, they are packaged into 
lipoproteins [very low density lipoproteins (VLDL), low density lipoproteins (LDL) and high 
density lipoproteins (HDL)] which are released back into the circulation (Mitra & Metcalf, 2009; 
Brown & Goldstein, 1986). The balance between fatty acid esterification and beta-oxidation is 
regulated by the hormones insulin and glucagon secreted from the pancreas. Whereas insulin 
stimulates the formation of triglycerides, glucagon stimulates the process of beta-oxidation 
(Campbell, 2006b).  
The liver not only plays a role in fat digestion by producing bile, it is also involved in the 
regulation of plasma cholesterol. Hepatocytes have a highly developed and sensitive mechanism 
for regulating intravascular and intracellular levels of cholesterol. In a stressed state, cells import 
cholesterol to save energy. Cholesterol is acquired from the circulation by the uptake of 
lipoproteins, particularly LDL via LDL receptors. As the cellular requirement for cholesterol 
increases, the expression of the receptor increase and the serum LDL levels falls. On the contrary, 
if there is excess intracellular cholesterol, downregulation of the LDL receptor occurs while 
serum LDL levels rise. The amount of intracellular free cholesterol thus controls the expression 
of LDL receptors by stimulating or inhibiting the release of sterol regulatory binding protein 
(SREBP), which binds to DNA to promote transcription of the LDL receptor gene (Dietschy et 
al., 1993; Griffin, 2013). Another mechanism by which serum cholesterol can be decreased is 
through HDL. HDLs are produced in the gut and liver and once in circulation, increase in particle 
size by acquiring cholesterol from triglyceride rich lipoproteins and peripheral tissues. The 
cholesterol acquired undergoes a series of enzymatic reactions to form cholesterol esters which 
are transported back to the liver by HDL. The role of hepatic lipase in this context is to penetrate 
the surface of HDL to access the cholesterol core and retrieve the contents for the hepatocyte 
(Griffin, 2013).  
1.7.2 Carbohydrate metabolism 
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The portal vein and hepatic artery bring glucose to the liver following absorption from the small 
intestine. Glucose enters the hepatocytes via the glucose transporter 2 (GLUT2) situated on the 
hepatocyte cell membrane. The rate of glucose entry into the hepatocytes is directly proportional 
to the extracellular glucose concentration available within the hepatic portal vein and independent 
of insulin action. Inside the hepatocytes the enzyme glucokinase phosphorylates glucose 
molecules to produce glucose-6-phosphate which can follow one of two pathways: glycolysis or 
glycogenesis (Campbell, 2006b). During glycolysis, glucose-6-phosphate is metabolized to 
pyruvate in the cytosol and enters the mitochondria to partake in the citric acid cycle for energy 
production (Maughan, 2013). However, since the liver receives most of its energy from fatty acid 
and amino acid oxidation, the majority of the glucose absorbed will be converted to glycogen via 
glycogenesis and stored within the liver. The liver is the second largest glycogen store in the 
body after skeletal muscle. The enzyme glucose-6-phosphatase plays a role in the conversion of 
glycogen to glucose and this enzyme is not present in the muscle, only in the liver. Therefore, 
only the liver is able to contribute to blood glucose in the event of low blood glucose levels (Fig. 
1.3) (Campbell, 2006b).  
Figure 1.3: Hepatic glycogen synthesis and breakdown. Glucose enters the hepatocyte through the 
GLUT2 transporter. Glucokinase converts glucose to glucose-6-phosphate where this molecule can either 
enter glycolysis for energy production or glycogenolysis to form glycogen. Glycogen can also be 
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metabolized to glucose via the enzyme glycogen phosphorylase and glucose-6-phosphatase. These 
pathways are under the regulation of insulin which promotes glycogen formation and glucagon and 
catecholamines which promotes glycogen breakdown. Abbreviations: GLUT2 – glucose transporter 2 
(Adapted from Campbell, 2006b). 
For glycogenesis to occur, glucose-6-phosphate is first catalysed to glucose-1-phosphate and then 
synthesized into glycogen via the enzyme glycogen synthase. While insulin may not be required 
for glucose uptake it is essential for the activity of glycogen synthase to produce and store 
glycogen (Maughan, 2013). During fasting, glucagon stimulates the breakdown of glycogen to 
form glucose in a process termed glycogenolysis. Glycogen phosphorylase catalyses glycogen to 
glucose-1-phosphate and subsequently glucose-6-phosphate. Glucose-6-phosphatase reforms the 
latter into glucose which is released into circulation (Dashty, 2013). Glucagon is however not the 
only protein that is able to stimulate glycogenolysis. Under conditions of stress, catecholamines 
stimulate glycogenolysis, while insulin during the fed state facilitates glycogenesis. In addition, 
the liver can produce glucose from other nutrients such as alanine, lactate and glycerol, via a 
process known as gluconeogenesis (Maughan, 2013). The other hormones that are known to 
regulate gluconeogenesis in addition to glucagon are cortisol, as well as catecholamines. A 
healthy relationship between glucagon and insulin is important to stimulate gluconeogenesis 
during starvation, where high levels of glucagon and a lack of insulin is required. During stress 
however, elevated levels of catecholamines and cortisol are additional stimuli that induce 
gluconeogenesis (Campbell, 2006b). 
1.7.3 Protein metabolism 
The processes of protein synthesis and degradation are tightly controlled throughout the body so 
that total body protein levels are kept constant. The liver metabolizes proteins by catalysing 
transamination and deamination reactions. The liver also synthesizes urea as well as some plasma 
proteins.  Transamination is the transfer of an amino group (-NH2) from one amino acid to an α-
keto acid (usually α-ketoglutaric acid) to form a new amino acid, glutamate, and α-keto acid from 
the original amino acid. The enzyme alanine transaminase (ALT) catalyses the transamination 
between the amino acid alanine and the keto acid, α-ketoglutarate, to produce pyruvate and 
glutamate. This enzyme can also be used as an indication of hepatic function, with its release into 
the circulation as indicative of liver damage (Thapa & Walia, 2007). In contrast, deamination is 
catalysed by the enzyme glutamate dehydrogenase, where -NH2 is removed from glutamate to 
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form ammonia (NH3) and α-ketoglutarate (Fig. 1.4) (Mitra & Metcalf, 2009). The α-keto acids 
generated from transamination and deamination become shunted into the citric acid cycle for 
energy production with the release of carbon dioxide (CO2) and water. The keto acids can also 
serve as precursors for glucose synthesis during gluconeogenesis (Campbell, 2006b). Considering 
that the NH3 generated from deamination is toxic to human tissues, the liver converts NH3 to urea 
through the ornithine cycle which is eventually excreted by the kidneys (Mitra & Metcalf, 2009). 
Apart from the metabolism of branch chained amino acids in skeletal muscle, the liver is the only 
place in the human body where urea is produced (Campbell, 2006b).  
Figure 1.4: Transamination and deamination reactions to metabolize amino acids. Transamination is 
the transfer of the amino group (-NH2) from one amino acid to an α-keto acid to form a new amino acid, 
usually glutamic acid. Deamination is the removal of the -NH2 from glutamate to form ammonia (NH3) 
and α-ketoglutarate. 
Plasma proteins produced in the liver include albumin, fibrinogen and globulins. Albumin, while 
essential in the maintenance of fluid balance within peripheral tissues, it also binds various 
substances contained within plasma including fatty acids, bile salts and the hormone thyroxine 
(Campbell, 2006b). Albumin is the most vital protein produced by the liver and is therefore used 
as an indicator of hepatic function. When the liver is damaged, serum albumin levels are 
significantly reduced and may also be influenced by nutritional status, osmotic pressure and 
hormonal balance. In this case, hypoalbuminemia is not specific for liver disease and occurs 
during malnutrition, nephrotoxicity and chronic protein-losing enteropathies as well (Thapa & 
Walia, 2007). Globulins are components of lipoproteins that transport lipids and cholesterol 
between the liver and other tissues. These proteins bind a variety of substances including cortisol 
and thyroxine, minerals such as iron and copper and vitamin B12. Blood components such as the 
clotting factor prothrombin and the substance involved in fluid balance, angiotensinogen, are all 
typical examples of globulins. The liver also produces insulin-like growth factor 1 (IGF-1) for 
growth, hepcidin for the inhibition of iron absorption and thrombopoietin for the production of 
platelets (Campbell, 2006b). 
Glutamate + NAD+ + water NH3
+ + α-Ketoglutarate + NADH + H+ Deamination:   
  α-Ketoglutaric acid + amino acid  Glutamic acid + α-Keto acid  Transamination: 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 12 
 
1.7.4 Metabolism of drugs and toxins 
The metabolism of toxic substances by the liver occurs in two phases. In the first phase, toxic 
metabolites are inactivated by a group of enzymes called the P450 system. While these enzymes 
are not restricted to the liver, they are expressed in other tissue types as well. During the second 
phase, the water solubility of the substance is then increased so that it can be excreted in the urine 
or in bile. Blood draining from the gastrointestinal tract can in some cases be contaminated with 
bacteria and endotoxins. Resident Kupffer cells attached to the endothelium in the sinusoids, 
come into direct contact with the blood draining from the gastrointestinal tract. These cells then 
aid in the clearing of the microbes and release pro-inflammatory cytokines, IL-1 and IL-6 in the 
process (Campbell, 2006b). Additionally, Kupffer cells remove worn-out erythrocytes from the 
circulation and excrete the degradation product bilirubin within the bile (Sherwood, 2013). Based 
on the above roles, the liver is a vital organ involved in the execution of a variety of processes 
fundamental for the functioning of the human body. However, like any other organ, it is 
vulnerable to intracellular and extracellular damage that can affect its overall function.  
 
 
2. Doxorubicin 
Doxorubicin (DOX), also known as Adriamycin is an anthracycline antibiotic first isolated in the 
late 1960s from the fungus Streptomyces peucetius (Thorn et al., 2011; Minotti et al., 2004). This 
anthracycline has shown great potential in the eradication of cancerous cells and is classified by 
the Food and Drug Administration as one of the most effective antitumor drugs ever developed 
and as such, it is the most widely used chemotherapeutic agent for the treatment of cancers of the 
breast, aggressive lymphomas, solid tumours and soft tissue sarcomas (Carvalho et al., 2009; 
Tacar et al., 2013). 
2.1 Pharmacokinetics 
Following intravenous administration, the distribution half-life of DOX is between three to five 
minutes (mins) indicating the rate at which DOX is cleared from the plasma and taken up by the 
cells (Tacar et al. 2013). DOX enters cells via passive diffusion and once in the cytoplasm, it 
attaches to the 20s subunit of proteasomes, where it is translocated to the nucleus (Minotti et al., 
2004). It has been reported that the amount of DOX in the nuclear compartment is 50-fold higher 
compared to the amount found in the cytosplasmic compartment, reaching a saturation level of 
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340 µM. This can be represented as one DOX molecule intercalated at every fifth DNA base pair 
on a deoxyribonucleic acid (DNA) strand (Lal et al., 2010). Approximately 2% of DOX is left 
unbound in the cytoplasm and is distributed among other organelles that include the Golgi 
apparatus, mitochondria and lysosomes (Tacar et al., 2013). DOX penetrates cells effectively and 
can remain inside due to its lipophilic and DNA intercalating properties. However, despite these 
characteristics, DOX is unable to cross the blood brain barrier (Lal et al., 2010). Due to the livers 
role in metabolism, DOX appears to accumulate in this organ where it becomes biochemically 
transformed into doxorubicinol by the enzymes aldo-ketoreductase and ubiquitous cytoplasmic 
carbonyl reductase (Tacar et al., 2013; Kassner et al., 2008). Approximately 50% of DOX leaves 
the body unchanged whilst the other 50% undergoes metabolism (Kassner et al., 2008). As with 
all pharmacological agents, DOX needs to be eliminated from the body. The elimination of DOX 
from tissues takes much longer than its uptake, with a terminal half-life of 24-36 hours (hrs). The 
hepato-biliary pathway mediates plasma clearance with half of the excreted drug present in the 
bile. This is usually excreted from the body within five to seven days following chemotherapy. 
During the same period, 5-12% is excreted in the urine with 3% of the drug being the metabolite, 
doxorubicinol. Defecation contributes 10-20% towards the elimination of the drug after 24 hrs 
and after 150 hrs 50% of the drug is excreted via this route (Tacar et al., 2013). In experimental 
animal models, DOX is often administered via intraperitoneal injection. DOX administered via 
this route results in a bioavailability of 40% without altering the elimination capacity. In addition, 
there is twice the prolongation in the mean residence time (average amount of time a single drug 
molecule stays in the body) via the intraperitoneal route over the intravenous route (Nagai et al., 
2013).   
2.2 Doxorubicin’s mechanism of action against cancer cells 
DOX mainly kill cancer cells through DNA damage, while causing damage to other tissue types 
via oxidative stress, apoptosis and organelle dysfunction (Minotti et al., 2004). DOX directly 
causes damage to DNA by two mechanisms: DNA intercalation and the inhibition of 
topoisomerase (Mizutani et al., 2005). DOX prevents DNA replication and RNA transcription by 
spontaneously inserting itself between DNA base pairs in a mechanism referred to as 
intercalation. Single and double stranded DNA breaks induced by topoisomerase I and II activity, 
respectively, have also been observed following DOX treatment. (Cummings et al., 1991). 
During the cell cycle phase, the topoisomerase enzymes cause DNA strand breaks to modify the 
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supercoiled structure of DNA. These breaks can be resealed again after replication or 
transcription has been completed. However, DOX exploits topoisomerase II activity by 
stabilizing the reaction intermediate in which DNA strands are cut and bound to topoisomerase II. 
This subsequently hampers DNA resealing resulting in cell cycle arrest and death (Minotti et al., 
2004). Although DOX is an effective chemotherapeutic agent, its use is limited due to toxic 
effects observed in non-cancerous cells. Up until now, research has focused on the detrimental 
effects of DOX on cardiac tissue, while paying little attention to other organs. Therefore, the 
following mechanisms to be discussed are based mainly on observations from cardiac tissue with 
supporting literature relevant in the context of the liver. 
2.3 Doxorubicin-induced toxicity 
2.3.1 Oxidative stress 
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DOX is a potent inducer of oxidative stress. Following metabolic activation once taken up by the 
cells, it generates free radicals by one electron being removed from ring C and donated to 
NADPH to form a semiquinone radical. In the presence of oxygen (O2), the newly formed 
semiquinone donates its unpaired electron to O2 to generate superoxide (O2.-). The semiquinone is 
then regenerated to its native form, where the cycle continues. This is known as “redox cycling” 
and the other enzymes involved in this process are the oxidoreductases (NADPH cytochrome 
P450 reductase, mitochondrial NADH dehydrogenase, endothelial nitric oxide synthase and 
xanthine oxidase) (Fig. 1.5) (Minotti et al., 2004; Keizer et al., 1990). DOX “redox cycling” 
occurs in the nucleus, mitochondria, ER as well as the cytoplasm, and the free radicals generated 
are responsible for the cytotoxic damage of these organelles (Keizer et al., 1990). Considering 
that the liver is responsible for the metabolism of DOX, and hepatocytes are rich in mitochondria 
and ER, it is thus likely that DOX induces similar oxidative damage to these organelles in this 
organ. 
Figure 1.5: The chemical structure of DOX and redox cycling of the quinone moiety. (A) Structure of 
DOX with the quinone moiety circled in blue. (B) The Redox cycling of DOX, one electron is removed 
from the quinone moiety to NADPH, forming a semiquinone. The latter donates the electron to O2 
generating O2·- and subsequently H2O2.  Abbreviations: DOX – doxorubicin, O2 – oxygen, O2·- - 
superoxide, H2O2 – hydrogen peroxide (Adapted from Minotti et al., 2004). 
 
Furthermore, DOX and the O2·- anions generated also disrupts intracellular iron (Fe) homeostasis 
which accelerates the generation of reactive oxygen species (ROS). In this case, the iron binding 
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protein, ferritin, and the iron regulatory protein (IRP) are targeted. Ferritin is responsible for the 
intracellular storage of iron, and when O2·- anions are produced from the metabolic activation of 
DOX, they enter the transprotein channels of ferritin to reduce the iron core resulting in the 
release of ferrous iron (Fe2+). As the semiquinone has a lower reduction potential than O2·- 
anions, it is unable to enter the iron core of ferritin (Minotti et al., 2004). The IRP aconitase, 
located in the mitochondria and cytoplasm, contains an iron-sulphur [4Fe-S] cluster within its 
catalytic site. In the mitochondria this enzyme converts citrate to isocitrate as part of its role in 
the citric acid cycle. When the enzyme is present in the cytoplasm, it participates in iron 
regulation and is referred to as IRP-1 (Ghigo et al., 2016). O2·- and hydrogen peroxide (H2O2) 
free radicals sequester the fourth iron from the [4Fe-S] aconitase catalytic site to form [3Fe-S]. 
This event results in a protein that contains [3Fe-S] and is devoid of aconitase activity. The 
release of the iron cluster transforms cytoplasmic aconitase into the IRP-1 where it binds with 
high affinity to the conserved iron-responsive elements in the untranslated regions of the 
transferrin receptor and ferritin messenger ribonucleic acids (mRNAs). This reduces the 
expression of ferritin, while increasing that of the transferrin receptor (Ghigo et al., 2016; Minotti 
et al., 2004). The transferrin receptor recruits transferrin from the circulation into the cell and 
thereby increasing the intracellular free iron concentration. Together, the sequestration of Fe2+ 
from ferritin and [Fe-S] from aconitase, leads to a reduction in the production of ferritin while 
increasing expression of the transferritin receptor. This results in elevated free cytoplasmic iron 
and the formation of DOX-iron (DOX-Fe) complexes (Ghigo et al., 2016).  
Free intracellular iron promotes ROS generation not only via the Fenton and Harber-Weiss 
reactions but also through the above mentioned DOX-Fe complexes. Normally, the O2·- generated 
from DOX is dismutated to H2O2 by the anti-oxidant superoxide dismutase (SOD), where after 
H2O2 is eliminated by glutathione or catalase (CAT). H2O2 and O2·- could also follow a different 
route under normal physiological conditions, where in the presence of iron, H2O2 and O2·- are 
readily converted to hydroxyl radicals (OH-). As indicated in Fig.1.6 below, the Harber-Weiss 
reaction may occur on its own at a slow rate (equation 1), while in the presence of iron (Fe2+) this 
reaction occurs much faster (equation 2). The Fe catalysed Harber-Weiss reaction involves the 
reduction of ferric iron (Fe3+) to ferrous iron (Fe2+) by O2·-, followed by the Fenton reaction in 
which Fe2+ catalyses the conversion of H2O2 into toxic OH- radicals (equation 3). DOX-Fe3+ 
complexes are reduced to DOX-Fe2+ in the presence of a reducing system, namely NADPH 
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cytochrome P450 reductase, cysteine or glutathione thiol residues. DOX-Fe2+ in turn reacts with 
O2 to form O2·- and subsequently OH- radicals. In the absence of the reducing enzymes, DOX-
Fe3+ undergoes oxidation, generating a DOX-Fe2+ complex. This complex catalyses O2 to form 
O2·- anions which react with H2O2 to generate OH- radicals (Šimůnek et al., 2009). The free 
radicals generated cause lipid peroxidation of unsaturated fatty acids present on cellular and 
organelle membranes. This process produces toxic aldehydes such as malondialdehyde (MDA) 
which diffuses within cells and attacks macromolecular targets far from where they were 
generated. They thus act as secondary cytotoxic messengers (Keizer et al., 1990; Luo et al., 
1997). Free radicals further oxidize DNA and proteins leading to the inhibition of enzymes 
necessary for cellular function. Furthermore, the cytotoxic aldehydes result in impaired energy 
production, macromolecular damage, and the elicitation of an inflammatory response that 
culminates in cell death following organelle dysfunction (Keizer et al., 1990; Luo et al., 1997). 
Figure 1.6: The Harber-Weiss and Fenton reaction. O2·− and H2O2 are converted to hydroxyl radicals 
by the Harber-Weiss reaction at a slow rate (equation 1). In the presence of Fe, the Harber-Weiss reaction 
occurs at faster rate and involves the Fenton reaction where O2·−  is catalysed to O2 by Fe3+(equation 2) 
followed by Fe2+ catalysing the conversion of H2O2 to hydroxyl radicals (equation 3). Abbreviations: O2· − 
- superoxide, H2O2 – hydrogen peroxide, Fe – iron, Fe3+ - ferric ion, Fe2+ - ferrous ion. 
2.3.2 Mitochondrial and ER dysfunction 
DOX has previously been shown to associate with the mitochondria and ER. While it is not clear 
which protein it binds to on the ER, it binds with high affinity to cardiolipin, an integral protein 
enriched in the inner mitochondrial membrane (Sishi et al., 2013a, Sishi et al., 2013b; C Pereirra 
et al., 2011). The binding of DOX to cardiolipin prevents creatine kinase binding to the inner 
mitochondrial membrane and decreases the activity of mitochondrial enzymes dependent on 
cardiolipin (Carvalho et al., 2009). In this case, cardiolipin is not able to interact with key 
Harber-Weiss reaction:   O2·− + OH
- + OH·
O2·−  + Fe
3+ O2 + Fe
2+
O2·− + H2O2 
Fenton reaction:  OH· + OH- + Fe3+H2O2 + Fe2+
equation 1 
equation 2 
equation 3 
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mitochondrial complexes and this consequence has severe implications for oxidative 
phosphorylation and adenosine triphosphate (ATP) production (C Pereirra et al., 2011). The 
binding of DOX to complex I of the respiratory chain also generates single electrons that are 
transferred to DOX. Similar to the metabolic activation of DOX described previously, a 
semiquinone intermediate is formed which donates electrons to O2 producing the O2·- free 
radicals. This ROS further damages mitochondrial nucleic acids, proteins and lipids. DOX-
induced ROS oxidizes thiol residues of the mitochondrial membrane permeability pore (mPTP) 
resulting in their opening and the leakage of cytochrome c which initiates the intrinsic 
(mitochondrial) pathway of apoptosis (Carvalho et al., 2009; Mizutani et al., 2004; Ow et al., 
2008). Once in the cytosol, cytochrome c and the initiator caspase, procaspase 9, bind to 
apoptotic protease activating factor-1 (APAF-1) to form the apoptosome complex. This results in 
the activation of caspase 9, who activates the effector caspase, caspase 3 and finally the execution 
of apoptosis (Ow et al., 2008; Elmore et al., 2007; Raychaudhuri et al., 2010).  
DOX also interferes with the ability of the ER to regulate calcium (Ca2+) homeostasis. When 
DOX binds to the ER, it triggers Ca2+ release causing an increase in cytosolic Ca2+ concentration 
(Hanna et al., 2014). As the ER is in close proximity to the mitochondria, and the mitochondria 
are also involved in Ca2+ regulation, Ca2+ is taken up via the Ca2+ uniporter in an attempt to 
restore Ca2+ homeostasis. When the Ca2+ concentration within the mitochondrial matrix reaches 
and exceeds its threshold, the mPTP opens where cytochrome c leaks and apoptosis is induced 
(Deniaud et al., 2007). The ER not only functions as the Ca2+ storage center, the majority of 
membrane and secreted proteins are folded within this organelle where they are released 
extracellularly or incorporated into cellular compartments (Zhang & Kaufman, 2008; Meusser et 
al., 2005; Shu et al., 2012; Høyer-Hansen & Jäättelä, 2007). Therefore, the ER has a quality 
control mechanism where only properly folded proteins are released and the misfolded proteins 
are translocated to the cytosol for proteasomal degradation in a process termed ER associated 
protein degradation (ERAD) (Walter & Ron, 2011). As the ER is sensitive to changes in redox 
status, as observed during DOX treatment, the ER folding capacity and assembly is disrupted 
resulting in the build-up of misfolded proteins within the ER lumen. This series of events induces 
ER stress and the cell responds by stimulating the unfolded protein response (UPR) in an attempt 
to clear these proteins from the lumen. In addition, the UPR inhibits protein translation and 
upregulates signalling pathways that increase the production of molecular chaperones that assist 
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in the removal of these damaged proteins (Suh et al., 2010). The UPR is initiated by protein 
sensors localized on the ER membrane. These include inositol-requiring 1α (IRE1α), double-
stranded RNA-dependent protein kinase-like ER kinase (PERK) and activating transcription 
factor 6 (ATF6). Under normal conditions, these proteins are maintained in position by glucose 
regulated protein 78 (Grp78), also known as binding immunoglobin protein (BiP). During ER 
stress, BiP is recruited to bind with unfolded or misfolded proteins and thereby releases the ER 
stress sensors, resulting in their activation. IRE1, PERK and ATF6 act to upregulate ER 
chaperones to increase the protein folding capacity of the ER and to initiate the ERAD pathway 
to clear misfolded proteins (Zhang & Kaufman, 2008; Tsai & Weissman, 2010; Rutkowski & 
Kaufman, 2007). ERAD involves the translocation of misfolded ER proteins to the cytoplasm 
where they are degraded by the ubiquitin proteasome pathway (UPP) in a Lysine48 (K48)-
dependent manner. (Lecker et al., 2006; Benbrook & Long, 2012).  
IRE1, PERK and ATF6 act by signalling downstream proteins to achieve the desired effects (Fig 
1.7). Once activated, IRE1 splices an intron from the X-box-binding protein 1 (XBP1) mRNA 
leading to the translation of the XBP1. XBP1 upregulates the expression of ER chaperones to 
assist in protein folding, and activates the apoptosis signalling-regulating kinase 1 (ASK1). ASK1 
proceeds to activate Jun N-terminal Kinase (JNK) and p38 Mitogen-activated protein kinases 
(MAPKs) where JNK leads to ER stress-induced apoptosis and increased autophagy, while p38 
promotes cellular senescence (Tsai & Weissman, 2010). Activation of PERK results in the 
phosphorylation of eukaryotic initiating factor 2 subunit α (eIF2α) which inhibits overall protein 
translation and consequently reduces protein flux into the ER lumen for protein folding. 
However, eIF2α only prevents the translation of specific mRNAs into proteins, while others such 
as ATF4 continue to be translated. On the one hand, ATF4 stimulates the expression of ER 
chaperones and genes involved in the synthesis of glutathione, thereby resisting oxidative stress, 
and thus promoting cell survival. On the other hand, ATF4 stimulates the expression of C/EBP 
homologous protein (CHOP) which aggravates ER stress by increasing ER load and expression 
of the ER oxidase ER Oxidoreductin-1α (ERO1α), which makes the ER lumen more acidic. 
CHOP therefore acts to induce cell death. ATF6 is first translocated to the Golgi apparatus where 
it is cleaved by Golgi proteases resulting in its activation. It upregulates the expression of CHOP, 
ER chaperones and different components of the ERAD system. However, if these mechanisms 
fail and ER stress persists, the UPR stimulates autophagy to assist in the degradation of proteins, 
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and if autophagy cannot alleviate ER stress, apoptosis will then be activated (Tsai & Weissman, 
2010; Walter & Ron, 2011). 
Figure 1.7: Downstream signalling effects of ATF6, IRE1 and PERK during the UPR.  ER stress 
initiates the UPR leading to the activation of ATF6, IRE1 and PERK. These proteins initially function to 
resolve ER stress. ATF6 becomes cleaved and upregulates ER chaperones and the ERAD. IRE1 activates 
two proteins. First, it splices XBP1 mRNA leading to its activation. XBP1 then upregulates ER 
chaperones and autophagy.  Second, it activates ASK1 who upregulates autophagy and senescence via 
JNK and p38, respectively. PERK inhibits eIF2α leading to the inhibition of protein translation and the 
activation of ATF4 who also upregulates ER chaperones and autophagy. Sustained ER stress may cause 
the UPR to aggravate ER stress and cause cell death.  The proteins then upregulate CHOP, redox enzymes 
and induce apoptosis. Abbreviations: ER – endoplasmic reticulum, UPR – unfolded protein response, 
ATF6 - activating transcription factor 6 IRE1- inositol-requiring 1, PERK - protein kinase-like ER 
kinase, XBP1 - X-box-binding protein 1, ASK1 – apoptosis signalling-regulating kinase 1, JNK 
– Jun N-terminal Kinase, eIF2α - eukaryotic initiating factor 2 subunit α, ATF4 activating 
transcription factor 4, ERAD – ER associated degradation, CHOP - C/EBP homologous protein 
(Adapted from Tsai & Weissman, 2010). 
 
2.4 Autophagy 
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Autophagy occurs in three forms in a cell: macroautophagy, chaperone-mediated autophagy and 
microautophagy. Macroautophagy (referred to as autophagy from this point on) is the degradation 
of long-lived proteins and organelles sequestered in autophagosomes. The autophagosomes fuse 
with lysosomes where the contents are digested and released within the cell for recycling. 
Chaperone-mediated autophagy entails the binding of specific proteins by heat shock protein 70 
(Hsc70) and these proteins are transported directly to the lysosome for degradation. 
Microautophagy necessitates that lysosomes directly engulf defective proteins and organelles 
where they are immediately digested (Orrenius et al., 2013; Benbrook & Long, 2012). While all 
forms of autophagy occur at basal levels, they are upregulated to suprabasal levels in response to 
various stimuli that include oxidative and ER stress, as well as nutrient deprivation (Benbrook & 
Long, 2012). While Tsai and Weissman (2010) report that the UPR activates autophagy through 
the IRE1-ASK-JNK axis, others indicate that UPR appears to mediate autophagy through the 
PERK-eIF2α axis (Suh et al., 2012; Høyer-Hansen & Jäättelä, 2007). 
 
While in the event of ER stress the UPR may induce autophagy, the autophagy pathway may also 
step in on its own, mediated by adapter proteins such as p62. Usually, the ubiquitin proteasome 
pathway (UPP), a major degradative pathway, determines whether a protein will be degraded via 
the UPP or autophagy (Benbrook & Long, 2012). The UPP involves the covalent attachment of 
ubiquitin (Ub) molecules to the protein substrate followed by degradation by the proteasome. The 
topology of the Ub chain mediates this process.  The proteins may be tagged with multiple Ub 
molecules that form a chain. This chain of Ub molecules can be branched on any of the internal 
lysine (K) residues (Shang & Taylor, 2011). The proteins tagged with polyubiquitin chains 
branching at K48 have a more closed conformation and will be degraded via the UPP. While 
proteins with a single Ub molecule or branched on other Lysine residues are degraded via 
autophagy. Some proteins may be degraded by either pathway (Benbrook & Long, 2012). The 
degradation path to be followed is determined by adapter proteins, p62 and neighbour of BRCA1 
(NBR), which shuttle proteins to autophagic vesicles or the adapter proteins, p97, which shuttle 
proteins to the proteasome. On the one hand p62, has a high affinity for monoubiquitinated and 
K63 tagged proteins, and these proteins are targeted for autophagic degradation. On the other 
hand, p62 can also recognize K48 polyubiquitin chains that are targeted for proteasomal 
degradation. This means that in the event of proteasome overload or dysfunction, p62 can target 
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proteins meant for proteasomal degradation to autophagic vesicles for degradation (Benbrook & 
Long, 2012; Popovic & Dikic, 2012).  
 
Sustained ER stress can signal apoptotic cell death via the UPR. CHOP and JNK are reported to 
play essential roles in the induction of cell death in this context. CHOP downregulates the anti-
apoptotic protein B-cell lymphoma 2 (Bcl-2), upregulates Bcl-2 homology domain 3 (BH3)-only 
proteins and the growth arrest and DNA damage-inducible protein 34 (GADD34). The latter 
functions to inhibit eIF2α and thus releases the suppression on protein translation. This will 
subsequently increase ER load and aggravate ER stress. JNK phosphorylates Bcl-2 and BH3-only 
proteins that promote apoptosis (Suh et al., 2012). Furthermore, it has previously been reported 
that unrestrained autophagy may induce cell death independently of apoptosis resulting in a loss 
of viable cell mass, or disrupting the balance between pro-survival and pro-apoptotic proteins 
(Benbrook & Long, 2012).  
Taken together, all of the above indicate that DOX toxicity on healthy tissue is a multifactorial 
process. Not only does DOX cause damage through organelle dysfunction and apoptosis 
potentially as a result of oxidative stress, much of the literature has focused on reducing oxidative 
stress to prevent oxidative damage with the use of various antioxidants. While the anti-oxidative 
agents employed successfully reduced oxidative damage in cellular and pre-clinical models, 
unfortunately these agents failed to provide the same effects clinically (Minotti et al., 2004). 
What this means is that we don’t have a full understanding of the mechanisms involved that 
govern toxicity and its downstream effects. Thus, we should aim to investigate other treatment 
options that not only target oxidative stress, but other mechanisms that are induced as a result of 
oxidative stress. 
 
3. Ghrelin 
The hormone ghrelin has been characterized as a 28 amino acid peptide with an octanoic acid 
attached to the third serine residue. It was first discovered as a growth-hormone secretagogue 
(GHS), stimulating the pituitary to release growth hormone (GH) (Kojima et al. 1999). It was 
later found to also stimulate the release of adrenocorticotropic hormone (ACTH) and prolactin 
from the pituitary as well (Delhanty et al., 2006). Since its discovery, research has shown that 
this hormone not only acts on the brain, but also the gut and other organs to regulate metabolism. 
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Today, ghrelin is well-known for its role in energy homeostasis and within the last decade, 
several in vivo studies have demonstrated that ghrelin has anti-oxidative, anti-inflammatory and 
anti-apoptotic properties (Çetin et al., 2011; Koyuturk et al., 2012; Dobutuvic et al., 2013; Li et 
al., 2012). 
3.1 Synthesis and half-life 
The synthesis of ghrelin entails the cleavage of a 117-amino acid pre-prohormone into either a 28 
amino acid protein with a C-terminal arginine, or a 27 amino acid protein with a C-terminal 
proline. The cleaved pre-prohormone undergoes posttranslational modification where the enzyme 
ghrelin O-acyltransferase (GOAT), found in the ER, acetylates the third serine residue with n-
octanoic acid or n-decanoic acid (Hosoda et al., 2003; Castañeda et al., 2010). This acetylation is 
crucial for ghrelin to interact with its receptor and affects its passage across the blood brain 
barrier (Leite-Moreira & Soares, 2007). While ghrelin is also produced in rodents, it differs by a 
mere 2 amino acids from the ghrelin expressed in humans (Lysine 11 and Alanine 12 in humans, 
Arginine11 and Valine12 in rodents) (Hosoda et al., 2003). The pharmacokinetics of total ghrelin 
elimination from plasma is suggested to be 27-31 mins and that of active ghrelin, a half-life of 9-
13 mins (Akamizu et al., 2004). Ghrelin can be removed from the circulation by enzymatic 
degradation or by binding to lipoproteins that will prevent interaction with its receptor 
(Castañeda et al., 2010). 
3.2 Distribution 
Ghrelin is mostly produced by the X/A-like cells present in the digestive tract (Date et al., 2000; 
Sehirli et al., 2008). The X/A-like cells of the oxyntic mucosa in the gastric fundus produce two-
thirds of plasma ghrelin and the rest by those found in the small intestine. Other organs that 
produce relatively less ghrelin include the kidneys, pancreas, lymphatic tissue, placenta, thyroid 
and adrenal gland, gonads, heart, eyes, lungs, pituitary and the hypothalamus. It is highly 
improbable however that the ghrelin produced by these other organs is released into circulation, 
but rather is used for autocrine or paracrine function (Leite-Moreira & Soares, 2007). 
Interestingly, while ghrelin may have physiological importance, the biological function of ghrelin 
in many different tissues is still unclear (Castañeda et al., 2010). 
3.3 Stimulators and inhibitors of ghrelin secretion 
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Hormones that supress ghrelin secretion include insulin, GH, somatostatin and cortistatin. GH’s 
repressing action on ghrelin secretion indicates a negative feedback loop between the 
hypothalamus and the stomach, as ghrelin stimulates the release of GH. Secretion of ghrelin is 
stimulated by acetylcholine, oestrogen, testosterone, IGF-1 and combined administration of 
growth-hormone-releasing-hormone (GHRH) and arginine (Leite-Moreira & Soares, 2007). 
Since ghrelin is known for its orexigenic properties, it is thus influenced by nutritional status; 
where during fasting glucose and lipid levels are low, or during conditions such as anorexia 
nervosa and cachexia, ghrelin levels are upregulated. In contrast, during feeding or obese states, 
circulating plasma levels of ghrelin are downregulated or dysregulated (Barazzoni et al., 2005; 
Smith et al., 2005). 
3.4 Receptor distribution, interaction and transduction pathways 
Ghrelin acts through its G-protein coupled receptor, growth hormone secretagogue receptor 
(GHS-R), which has two isoforms; GHS-R1α and GHS-R1β (Kojima et al., 1999; Smith et al., 
2005). Ghrelin acts through the GHS-R1α largely found in the arcuate nucleus, an area in the 
hypothalamus essential for the neuroendocrine and orexigenic properties of ghrelin, as well as in 
the somatotroph pituitary cells (Muccioli et al., 2002). Although, the GHS-R1α has not been 
found on hepatocytes, ghrelin has been found to stimulate glucose output in hepatocytes, thus 
suggesting an uncharacterized receptor for ghrelin on liver tissue exist (Gauna et al., 2005). The 
binding of ghrelin to its receptor induces the activation of different signalling transduction 
pathways on different tissues through the increase in intracellular Ca2+. For example, in pituitary 
cells, ghrelin activates the phospholipase C (PLC)/diacylglycerol (DAG)/Inositol trisphosphate 
(IP3) signalling pathway, while in neuropeptide Y (NPY) expressing cells of the arcuate nucleus, 
ghrelin stimulates adenylate-cyclase/cyclic adenosine monophosphate (cAMP)/protein kinase A 
(PKA) pathway (Muccioli et al., 2002: Castañeda et al., 2010). In vascular epithelium ghrelin 
acts to inhibit inflammation by activating the calmodulin-dependent kinase kinase (CAMKK), 
AMP-activated protein kinase (AMPK) and endothelial nitric oxidase synthase (eNOS). AMPK 
activation in the hypothalamus regulates food intake in response to fasting (Castañeda et al., 
2010). Due to the variation in signalling pathways activated in different tissue types, it is clear 
that the activation of the GHS-R1α signal transduction pathway is tissue and function specific 
(Leite-Moreira & Soares, 2007). 
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3.5 Ghrelin’s role in metabolism 
Ghrelin has always been thought to play a fundamental role in metabolism by stimulating food 
intake with a subsequent increase in the adiposity index (Wortley et al., 2004). Literature also 
indicates that ghrelin does not regulate energy homeostasis directly but rather other mechanisms 
compensate for ghrelin’s appetite stimulating properties. Ghrelin’s orexigenic properties are 
compensated for by the NPY and agouti-related protein (AgRP) neurons which co-localize with 
GHS-R1α in the arcuate nucleus found in the nutrient centre of the brain. By ghrelin binding to 
this receptor in this region, it triggers spontaneous activity of NPY and AgRP neurons (Albarrab-
Zeckler et al., 2011; Müller et al., 2015). Therefore, the activity of ghrelin in the brain could 
modulate both appetite and body weight. Although ghrelin appears to indirectly stimulate 
appetite, other studies have demonstrated that ghrelin acts directly on peripheral tissues and to 
regulate metabolism and/or digestion (Gauna et al., 2005). In this scenario, ghrelin promotes 
gastric motility, as well as gastric acid secretion and is also involved in carbohydrate and lipid 
metabolism (Van der Lely et al., 2004). Ghrelin’s role in carbohydrate metabolism is to increase 
plasma glucose levels by stimulating glycogenolysis and gluconeogenesis in hepatocytes (Leite-
Moreira & Soares, 2007). Barazonni and colleagues (2005) reported that prolonged ghrelin 
treatment induces hyperglycemia by upregulating the activity of the glycolytic enzyme glucose-6-
phosphatase in hepatocytes. In return, glucose decreases ghrelin secretion. Vestergaard and 
colleagues (2008) demonstrated that ghrelin promoted peripheral insulin resistance through the 
inhibition of pancreatic β-cell function, while promoting hepatic glucose secretion in healthy 
young men. This study further reported that glucagon had no impact on ghrelin stimulating 
hepatic glucose production.  
In the context of lipid metabolism, exogenously administered ghrelin in rodents has been 
demonstrated to reduce 5' AMP-activated protein kinase (AMPK) levels, a potent inducer of fatty 
acid oxidation, and promote the expression of genes that favour lipogenesis and triglyceride 
storage in the liver. However in skeletal muscle, ghrelin reduces triglyceride content and 
upregulates the activity of mitochondrial oxidative enzymes independent of changes in AMPK 
levels (Barazonni et al., 2004). Furthermore, ghrelin activates peroxisome proliferator-activated 
receptor γ (PPARγ) which reduces fat content in skeletal muscle. Based on these findings, ghrelin 
favours the deposition of triglycerides in the liver rather than in skeletal muscle and acts on 
adipocytes to favour lipogenesis over lipolysis  
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3.6 Anti-oxidative, anti-inflammatory and anti-apoptotic properties 
Cellular systems are protected from harmful agents by having an endogenous anti-oxidant 
defence system consisting of anti-oxidants and enzymes. The anti-oxidants include reduced 
glutathione (GSH), vitamins A, C and E and the enzymes include reduced peroxidase (GPx) and 
glutathione reductase (GR), SOD and CAT (Jafari et al., 2007) The liver is responsible for the 
detoxification of drugs and toxins, therefore the liver should have a good anti-oxidant defence 
system. De novo synthesis of the anti-oxidant reduced GSH occurs in the liver, and is distributed 
to the rest of the body which contributes almost 90% of reduced GSH under normal physiological 
conditions. Although reduced GSH is distributed to other tissues, the liver still contains the 
highest reduced GSH concentration in the body (Limón-Pacheco & Gonsebatt, 2008). However, 
in disease states the anti-oxidant defence system may not be sufficient to prevent damage and 
additional help is required. Therefore, studies has investigated the effects of ghrelin in hepatic 
pathophysiology. 
The administration of ghrelin into the cerebro-ventricules of male Wistar rats was shown to 
upregulate protein expression of different intracellular antioxidant enzymes in the liver 
(Dobutovic et al., 2014). This indicates that ghrelin can promote protection against oxidative 
stress in hepatocytes. These findings have led ghrelin to be utilized as an adjuvant therapeutic 
agent in various pathological conditions. Li and colleagues (2013) reported that ghrelin 
administration during the induction of non-alcoholic fatty liver disease (NAFLD) reduced 
oxidative stress, restored the expression of GPx and reduced the pro-inflammatory cytokines, 
TNF-α and IL-6, at both the transcriptional and translation level. The decline in oxidative stress 
and pro-inflammatory cytokines was associated with a reduction in cleaved caspase 3 expression. 
Interestingly, a recent study conducted by Koyuturk and colleagues (2015) found that ghrelin 
does not reduce the rate of apoptosis in hepatocytes of diabetic neonatal rats. The controversial 
reports on the anti-apoptotic property of ghrelin could be due to variation in pathophysiological 
conditions and experimental models used.  
Moreover, ghrelin administration prior to inducing carbon tetrachloride toxicity in the rat liver, 
has shown increased activity of the anti-oxidant enzyme, SOD, CAT and GPx with a subsequent 
reduction in lipid peroxidation and inducible nitric oxide synthase (iNOS) (Cetin et al., 2011). 
Other studies have also utilized ghrelin as a therapeutic agent in hepatic pathology. Chronic 
cholestatic disease is characterised by damage to biliary epithelium that results in the defective 
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transport of bile from the liver to the intestine. This results in damage to hepatocytes that induces 
an inflammatory response and activation of Kupffer cells leading to hepatic fibrosis. Iseri and 
colleagues (2008) found that long term ghrelin treatment in chronic cholestatic hepatic injury 
decreased serum pro-inflammatory cytokines and serum lactate dehydrogenase (LDH) activity, 
while improving liver function. Furthermore, hepatic lipid peroxidation and collagen deposition 
were decreased.  The above in vivo studies on various hepatic pathologies exhibit ghrelin’s anti-
oxidative, anti-inflammatory, anti-apoptotic and in addition, anti-fibrotic properties.  
4. Summary
DOX is the most effective antitumor drug used against a wide range of cancers. However, its 
clinical use is limited due to the development of chronic cardiomyopathy and congestive heart 
failure (CHF) years after treatment, as a result of the toxicity on healthy tissues (Minotti et al., 
2004). Research has invested its resources into DOX-induced cardiotoxicity and has neglected to 
investigate potential damaging effects on other peripheral organs. The liver is responsible for 
metabolizing DOX, which has been found to accumulate in this organ. Tacar and colleagues 
(2013) reported that 40% of patients receiving DOX suffer from liver injury caused by oxidative 
stress. However, based on the above mentioned literature, DOX toxicity is multifactorial and 
therefore therapeutic interventions should also be multifactorial. Ghrelin is a hormone naturally 
found in the body which has been found to possess beneficial properties that could protect the 
liver against DOX toxicity. Up until now, the therapeutic role of ghrelin in a chronic model of 
DOX toxicity has not been evaluated. Therefore, this study hypothesises that long term DOX 
treatment induces toxicity in hepatic tissue that will negatively affect liver function while the use 
of ghrelin, will prevent the damaging effects induced by DOX. 
The aim of this study was to investigate: 
(i) The effect of DOX on liver function and if damaging effects are found, whether the 
use of ghrelin will improve liver function in the presence of DOX. 
(ii) DOX induced oxidative stress on liver tissue and the use of ghrelin as an intervention. 
(iii) Upregulation of autophagy, apoptosis and ER stress following DOX treatment alone 
and whether co-treatment with ghrelin will decrease these markers. 
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Chapter 2 
_________________________________________________________________ 
Materials and Methods 
2.1 Experimental procedure 
In an effort to investigate the effects of DOX on the liver, a model simulating chronic DOX-
induced cardiotoxicity was utilised. This disease is mainly observed in survivors of childhood 
cancer years to decades following DOX therapy. A repeated measures experimental design were 
utilised for this study. Four week old male Sprague-Dawley rats (90 – 130 g) were acclimatised 
for one week, where after they were randomly allocated into four experimental groups, namely: 
vehicle (n=7), DOX (n=9), ghrelin (n=7) and DOX+Ghrelin (n=9). While the vehicle group 
received physiological saline, the DOX group (LKT Laboratories, D5794, USA) received 2.5 
mg/kg once weekly, the ghrelin group (LKT Laboratories, G2869, USA) received 100 µg/kg 
three times a week and the DOX+Ghrelin group received both treatment regimens. All injections 
were conducted intraperitoneally (i.p) for a duration of eight weeks. Animals were housed in 
sterile rat cages at an ambient temperature of 25 °C with a 12hr light-dark cycle, while receiving 
standard rat chow and tap water ad libitum. All experiments were ethically approved and 
executed according to the guidelines for the care and use of laboratory animals implemented at 
Stellenbosch University (reference number: SU-ACUD15-00038) and conformed to the accepted 
standards for the use of animals in research and teaching as reflected in the South African 
National Standards 10386: 2008. Body weight measurements, food consumption and general 
well-being of the animals was monitored regularly. 
2.2 Sample collection 
One week after the last injection, the animals were euthanized with a lethal dose of sodium 
pentobarbitone (60 mg/kg) (Euthapent Kyron Laboratories, 130540, SA). Animals were checked 
for a pedal reflex before the abdominal cavity was cut open to harvest the liver. During this time, 
blood was collected from the thoracic cavity using a 10 mL syringe and immediately placed into 
plasma (Lasec, VGRV450474R, SA) and serum (Lasec, VGRV450470R, SA) separation tubes. 
Followed by centrifugation at 4000 rpm (1.4 x g) for ten minutes (4 °C), where after the plasma 
and serum was aliquoted at 200 µL volumes into centrifuge tubes and frozen at – 80 °C until 
required. The liver was weighed and examined grossly with the lobular segmentation counted 
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before it was divided into two parts. One half was snap frozen in liquid nitrogen for biochemical 
analysis, while the other was preserved in 4% formaldehyde (Merck Millipore, 1.00496.5000, 
SA) solution for histological staining.  
2.3 Liver function tests 
To determine the effects of this study’s treatment regimen on liver function, ALT (Abcam, 
ab105134, SA) and albumin (Abcam, ab108790, SA) concentration in the serum and plasma 
respectively, was evaluated using commercially available kits. Briefly, a standard curve was 
setup and a dilution series of the samples was performed to determine the appropriate 
concentrations of these proteins that fall within the range. After the reagents were prepared 
according to the manufacturer’s instructions, the samples were transferred into 96-well plates 
with their reaction reagents and the activity of ALT and albumin content was measured. ALT 
absorbance (BMG Labtech, SPECTROstar nano, Germany) was measured at a wavelength of 570 
nm at 37 ˚C every 2 minutes (mins) for a total of 60 mins, whereas albumin content was 
determined at room temperature at a wavelength of 450 nm (Bio-tek instruments Inc., EL800, 
USA). The absorbance measurements were then converted into mU/ml for ALT and µg/ml for 
albumin (see Appendix D, pg. 84 for full protocol). 
 
2.4 Histological Analysis 
2.4.1 Tissue processing and sectioning 
Liver tissue fixed in 4% formaldehyde underwent a series of dehydration steps followed by 
infiltration of Paraplast® wax (Sigma-Aldrich, A6330-4LB, SA) using a tissue processor (Sakura 
Finetechnical Co. Ltd, Tissue Tek II 4634, Japan). Once embedded onto a cassette (Lasec, 
PLPS191023, SA), tissue was sectioned into 5 µm thick sections with a microtome (Leica 
Biosystems, Leica RM 2125 RT, Germany) and placed onto glass microscope slides (Lasec, 
GLAS4S22M3000F, SA) (see Appendix E, pg. 90 for full protocol). The slides were then 
allowed to air-dry and adhere on a 20 °C heating block. 
 
2.4.2 Haematoxylin and Eosin stain 
The Haematoxylin and Eosin (H&E) stain was used to observe general histological structure of 
liver tissue. While acidic components such as the nucleus are stained blue by the haematoxylin 
dye, basic components such as the cytoplasm are stained pink by the eosin dye. This stain was 
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performed using an automated staining machine (Leica Biosystems, Leica ST5010 Autostainer 
XL, Germany), where micro- or macro-vesicular ballooning (hydropic changes) would be 
observed. The staining protocol followed is available in the Appendix section (see Appendix E, 
pg. 92 for full protocol). After staining, the slides were mounted using DPX mountant 
(Associated Chemical Enterprises, D0738NN00500, SA) and covered with a cover slip (Lasec, 
GLAS2C29M2250REC, SA). The slides were left to dry overnight. The stained slides were 
viewed using a bright-field Nikon ECLIPSE E400 microscope, mounted with a Nikon DS-Fi2 
camera, and processed through a Nikon Digital Sight DS-U3 processor (Nikon, Japan). Image 
processing was performed using NIS elements software v4.10. 
 
2.4.3 Masson’s Trichrome stain 
The Masson’s trichrome technique stains connective tissue to indicate fibrosis. The tissue 
sections were prepared as previously described and were deparaffinized and rinsed in distilled 
water. The slides containing tissue sections were placed in a haematoxylin solution for 5 mins 
followed by tap water until a dark blue colour formed. The sections were then placed in a 
working solution of fuchsin ponceau-orange G for 15 mins and rinsed in 0.2% acetic acid water 
(Radchem, 600113). The slides were flushed in 5% phosphotungstic acid (Merck Millipore, 
100582) for 5 mins and again rinsed in 0.2% acetic acid water to differentiate the colour tones. 
The sections were then stained in light green solution (Sigma-Aldrich, L1886, SA) for 20 min 
and treated with acetic acid for 5 min. This step was followed by dehydration through a series of 
alcohol solutions and xylene (Merck Millipore, 1086619190, SA) (see Appendix E, pg. 99 for 
full protocol). Finally, the slides were mounted using DPX mounting medium and covered with a 
cover slip. The stained slides were viewed using the same microscope as previously described. 
 
2.4.4 Reticulin stain 
The reticulin stain detects the reticulin fibres that form the supportive reticulin network in hepatic 
tissues. The tissue sections were prepared as previously described and slides were initially 
oxidized in 0.5% acidified potassium permanganate (Merck Millipore, 109930, SA), decolourised 
with 2% oxalic acid (Radchem, 6153-56-6, SA), fixed in 4% iron alum (Merck Millipore, 
103776, SA) and impregnated in ammoniacal silver solution. This was followed by reducing 
sections with 10% formalin, where after the slides were rinsed using tap water and distilled water 
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and fixed with 2% aqueous sodium triphosphate (Sigma-Aldrich, T5041, SA). Tissue slides were 
counterstained with light green solution (Sigma-Aldrich, L1886, SA) and after dehydration, 
slides were mounted using DPX mounting medium and covered with a cover slip. The stained 
slides were viewed using the same microscope as previously described (see Appendix E, pg. 95 
for full protocol). 
 
2.4.5 Periodic acid Schiff (PAS) stain 
The PAS stain was used to detect glycogen content in liver tissue. The tissue sections were 
prepared as previously described and slides were oxidized in 1% periodic acid solution (Sigma-
Aldrich, 210064, SA) rinsed in distilled water and placed in Schiff reagent (Merck Millipore, 
109034, SA) where the sections turned a light pink colour. After washing in lukewarm water, the 
sections developed into a dark pink colour. This was followed by counterstaining with Mayer’s 
haematoxylin (Merck Millipore, SAAR2822001LC, SA) and washing in tap water. The sections 
are then dehydrated and mounted accordingly. The stained slides were viewed using the same 
microscope as previously described (see Appendix E, pg. 97 for full protocol). 
 
2.4.6 Oil Red O stain 
The oil red O stain was used to observe lipid accumulation in hepatic tissue. For this stain, frozen 
liver tissue was placed in liquid nitrogen and sectioned into 7 µm thick sections with a cryostat 
(Leica CM 3050 S Research Cryostat, Leica Biosystems, Germany) and placed onto positively 
charged Histobond microscope slides (Lasec, GLAS2S13M0810401). The sections were left to 
defrost followed by placing in the oil red O staining solution (Sigma-Aldrich, O1391, SA)  The 
excess solution was briefly washed in cold tap water and counterstained with 50% crystal violet 
(Sigma-Aldrich, V5265) followed by another wash step using tap water. The sections were left to 
air dry, where after aqueous mounting media (Sigma-Aldrich, G 0918) was placed onto the 
sections with a coverslip. The stained slides were viewed using the same microscope as 
previously described (see Appendix F, pg. 104 for full protocol). 
 
2.4.7 Immunohistochemistry (IHC) 
The immunohistochemistry staining was used to stain for ALT in formaldehyde fixed liver tissue.  
The slides were sectioned as mentioned above and placed on positively charged glass microscope 
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slides. The IHC staining protocol was performed with an automated machine (Leica Biosystems, 
Bond-MaxTM Autostainer, Germany) and the BondTM Polymer Refine detection kit (Leica 
Biosystems, DS9800, Germany). An ALT primary antibody (Santa Cruz Biotechnology, sc-
271861, SA) was used to detect ALT present in the tissue using a horseradish peroxidase (HRP)-
linked antibody conjugate system (see Appendix E, pg. 100 for full protocol). ALT stained as a 
brown precipitate and was quantified with the IHC Profiler plugin in Image J version 1.50i. The 
software pixel intensity ranges from 0 to 255, with 0 representing the darkest shade and 255 the 
lightest shade of brown. With the assistance of a pathologist, the different shades were assigned a 
score where the darkest shade received a high score and the lighter shade a lower score. The 
scores were divided as high positive (3+), positive (2+), low positive (1+) or negative (0). The 
software determines the percentage (%) of pixels that falls within a category and if 60% or more 
falls within one category, that score is assigned to the image. If not, then the software uses an 
equation to assign a score to an image. The stained slides were viewed using the same 
microscope as previously described. 
 
2.5 Oxidative stress analysis 
As DOX is a known inducer of oxidative stress, oxidative damage was evaluated by measuring 
conjugated dienes (CDs), malondialdehyde (MDA) and glutathione. For these assays, 100 mg 
liver tissue was used and added to phosphate buffer (7.5 mM, pH: 7.4) in a 1:10 ratio. For the 
glutathione assay specifically, two separate assays were performed measuring reduced (GSH) and 
oxidized (GSSG) glutathione. For the GSSG assay, a similar process was followed but a solution 
of Methyl-2-vinylpyridinium triflate (M2VP) was added to the phosphate buffer and this solution 
was then added to the tissue. The tissue was subsequently homogenised (Kinematica AG, 
Polytron PT 2100, Switzerland) and then sonicated at an amplitude of 10 Hz for 10 seconds 
(secs) (Qsonica, Misonix Sonicator S-400, USA). The foam layer was allowed to settle after 
which the lysate was centrifuged (Labnet, Spectrafuge 16M, USA) at 4 ˚C at 12 000 rpm (9660 
g) for 10 mins. The supernatant was removed and used for further analysis (see Appendix G, pg. 
105 for full protocol). 
 
2.5.1 Conjugated Dienes 
The prepared tissue lysates were added to a solution of methanol and chloroform and centrifuged 
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 (Labnet, Spectrafuge 24D, USA) at room temperature at 14 000 rpm (13148 g). After the 
formation of a top protein layer and a bottom liquid layer, the liquid layer was removed and 
placed into centrifuge tubes and left overnight at 4 ˚C over a flow of nitrogen, where the 
chloroform and methanol solution evaporated and the fatty components left behind. Cyclohexane 
was added to each centrifuge tube, vortexed and the mixture was transferred into clear 96-well 
UV plates (Thermoscientific Inc, Microplate Uv Flat Bttm CS40, Netherlands). The conjugated 
diene (CD) content was measured with a spectrophotometer (Thermo Electron Corporation, 
Multiskan spectrum, Finland) at a wavelength of 230 nm. The absorbance measurements were 
converted into µmol CD/g of tissue (see Appendix G, pg. 106 for full protocol).  
 
2.5.2 TBARS assay 
The prepared tissue lysates were added to various reagents namely: 4 mM 3,5-Di-tert-4-
butylhydroxytoluene (BHT) (Sigma-Aldrich, 442377, SA), 0.2 M ortho-phosphoric acid (OPA) 
(Merck Millipore, 1.00573.2500, SA) and 0.11 M Thiobarturic acid (TBA) (T5500, Sigma-
Aldrich, SA). To catalyse the reaction, the mixture was vortexed and heated at 90 ˚C and the 
samples in centrifuge tubes were then placed into an ice bath to stop the reaction. Butanol 
(Sigma-Aldrich, B7906, SA) was added followed by centrifugation (Labnet, Spectrafuge 24D, 
USA) at room temperature at 14 000 rpm (13148 g). MDA content of each sample was measured 
with a spectrophotometer (Thermo Electron Corporation, Multiskan spectrum, Finland) at a 
wavelength of 532 nm in clear 96-well plates.  The absorbance measurements were converted 
into µmol MDA/g of tissue (see Appendix G, pg. 107 for full protocol).  
 
2.5.3 Glutathione assay 
As explained above, the liver tissue for GSH and GSSG measurement were prepared into lysates 
with two different buffers. The protocol used to measure GSH and GSSG remained the same. For 
each analysis, a standard curve was prepared and the lysates were transferred into clear 96-well 
plates. The following reagents were added to the lysates: 5,5'-dithiobis-(2-nitrobenzoic acid) 
(DTNB) (Sigma-Aldrich, D21820, SA), glutathione reductase (Sigma Aldrich, G3664, SA) and 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) (Sigma-Aldrich, N6785, SA). 
The plate was read with a spectrophotometer (Thermo Electron Corporation, Multiskan spectrum, 
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Finalnd) at 412 nm every 30 secs for 5 mins. Total GSH and GSSG were then calculated from the 
linear slope of the standard curve (see Appendix G, pg. 108 for full protocol). 
  
2.6 Western Blotting 
2.6.1 Preparation of tissue lysates 
Snap frozen liver tissue was thawed and protein was extracted by adding modified radio-
immunoprecipitation (RIPA) buffer (pH 7.4) followed by homogenization into a lysate 
(Kinematica, POLYTRON® PT 2100 Homogenizer Switzerland). The lysates were centrifuged 
(Labnet, Spectrafuge 16M, USA) at 14 000 rpm (13148 g) for 60 mins at 4° C to isolate the fat 
layer formed at the top, the protein layer in the middle and the pellet at the bottom of the 
centrifuge tubes. The fat layer was separated from the protein layer and the pellet discarded. To 
ensure that the protein layer was not contaminated, the lysate retrieved was centrifuged again for 
40 mins where after protein concentration was determined (see Appendix H, pg. 110 for full 
protocol).  
 
2.6.2 Protein determination 
The Direct Detect ™ Spectrometer (Merck Millipore, DDHW00010-WW, Germany) was used to 
determine the protein concentration within each lysate. This system measures the absorbance of 
amide bonds in protein chains using infrared quantitation thereby determines intrinsic 
components of every protein without relying on amino acid composition, dye binding properties 
and redox potential. 2 µl blank (RIPA buffer) and 2 µl of samples were pipetted onto the 
windows of the Direct Detect™ card. The card was then placed vertically inside the sampling 
accessory, which dries and then measures each sample as mg/mL of protein. 30 µg protein 
samples were prepared in Laemmli’s loading buffer, boiled at 95 ˚C for 5 mins and stored at -80 
°C until needed. In addition, the fat layer that was reserved was used to determine lipid content in 
each sample (see Appendix H, pg. 110 for full protocol). 
2.6.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Samples previously prepared in Laemmli’s buffer were thawed on ice and boiled again at 95 ˚C 
for five min. 30 μg protein of each sample was separated by 12% TGX stain-free™ FastCast™ 
acrylamide gels (Bio-Rad, 1610183, SA) for 10 mins at 100 V and 400 mA (constant), followed 
by 120 V for 60 mins. The stain-free gel was activated by placing the gel directly onto the Bio-
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Rad UV transilluminator plate (Bio-Rad, ChemiDoc™ XRS+ system, USA) and by selecting the 
‘gel activation’ step in the Image Lab™ software (Version 5.2.1). After activation, the proteins 
were transferred onto polyvinylidene fluoride (PVDF) membranes (Bio-Rad, Trans-Blot® 
Turbo™ ready-to-assemble mini low fluorescent PVDF transfer kit, 1707274, USA) using the 
TransBlot® Turbo™ Transfer System (Bio-Rad, USA) for 30 min at 25 V. After transfer, the 
stain-free blot was imaged for use in total protein normalization. Membranes were then blocked 
for 60 min at room temperature 5% fat free milk dissolved in 1x tris buffered saline-Tween®20 
Solution (1x TBS-T). After blocking, the membranes were washed 3 times for 5 min in 1x TBS-T 
and incubated overnight at 4 ˚C with gentle agitation in primary antibody (1:1000) dissolved in  
1X TBS-T (Table 2). Following primary antibody incubation, the wash step was repeated and the 
membranes were incubated in HRP-linked anti-rabbit or anti-mouse secondary antibody 
dissolved in 1x TBS-T for 60 mins at room temperature. Membranes were washed with 1x TBS-
T (3 x 5 min) and incubated with Clarity™ ECL western blotting substrate (Bio-Rad, 1705061, 
USA). The bands were detected using the ChemiDoc™ XRS+ System with the Image Lab™ 
software and discrepancies in loading were corrected for by using total protein normalization.  
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Table 2.1. List of primary and secondary antibodies used for Western blotting 
Abbreviations: PARP: Poly (ADP-ribose) polymerase, BiP: immunoglobulin heavy chain-binding 
protein, ATF4: Activating Transcription Factor 4, LC3: microtubule associated protein 1 light chain 3, 
ALT: alanine transaminase. 
2.7 Statistical analysis 
GraphPad Prism 5.0 (GraphPad Inc.) software was used for statistical analysis and visual 
representation of data. Statistical analysis was determined with one-way analysis of variance 
(ANOVA) followed by the Bonferonni posthoc test. All data are presented as mean ± standard 
error (SEM) and a p value less than (<) 0.05 was considered statistical significant. 
  
Primary Antibodies 
Name Size (kDa) Company (catalogue number) Dilution 
Cleaved Caspase-3 17, 19 
Cell Signalling Technology  
(9662) 
1:1 000 
Cleaved PARP 89 
Cell Signalling Technology 
 (5625) 1:1 000 
BiP 68 Cell Signalling Technology 
 (3177) 
1:1 000 
ATF4 48 
Cell Signalling Technology 
(11815) 
1:1 000 
LC3 16, 18 
Cell Signalling Technology 
 (3868) 1:1 000 
p62 62 Cell Signalling Technology  
(5114) 
1:1 000 
ALT 48 Santa Cruz Biotechnology 
 (Sc-271861) 
1:1 000 
 Secondary Antibodies 
Anti-Rabbit IgG HRP-
linked - 
Cell Signalling Technology 
 (7074) 1:10 000 
Anti-mouse IgG HRP-
linked 
- Cell Signalling Technology 
(58802) 
1:10 000 
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Chapter 3 
________________________________________________________________ 
Results 
3.1 Body weight 
Chemotherapeutic agents are known to result in weight loss in cancer patients, and considering 
that ghrelin promotes appetite, this study monitored body weight throughout the treatment 
duration. It was already evident by the fourth week that the DOX treated animals (228.30 g ± 
7.09 g, p < 0.01) were not gaining as much weight as the vehicle (control) treated animals 
(285.50 g ± 19.24 g). While comparing the DOX treated animals (247.30 g ± 6.51 g, p < 0.01) to 
the ghrelin treated animals, there was a significant difference (297.20 g ± 11.80 g) from the fifth 
week (Fig. 3.1). This lack of weight gain within the DOX group was maintained until the end of 
the treatment protocol. While the experimental animals that received both treatment regimens 
(DOX+Ghrelin) were affected by DOX, they fared better when compared to the DOX group, 
albeit insignificantly so. 
Fig. 3.1: Average body weight recorded per week. Body weight measurements recorded weekly per 
group following an eight week treatment regimen. Animals were treated (i.p) with saline (vehicle), DOX, 
ghrelin and a combination of the two drugs. Results are presented as mean ± SEM (n = 7-9). ** p < 0.01 
vs. vehicle, *** p < 0.001 vs. vehicle, $$ p < 0.01 vs. ghrelin and $$$ p < 0.001 vs. ghrelin.   Abbreviations: 
DOX – doxorubicin g – grams vs – versus.  
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3.2 Liver weight 
In contrast to how body weight was monitored, liver weight could only be measured at the end of 
the study. At face value, the weight of the livers in the DOX treated group appeared to be smaller 
(10.60 g ± 0.47 g, p < 0.001) versus the vehicle group (14.69 g ± 0.77 g) (Table 3.1), and no 
significant changes were observed in any of the other treatment groups. However, in order to get 
a better understanding of these results, the liver to body weight ratio was also calculated. When 
this was done, no considerable changes were observed and thus indicating that the weights of the 
livers were in proportion to the body weight of the animals in the different experimental groups. 
Table 3.1. Average body and liver weight and the ratio of liver to body weight at the end of the 
experimental procedure.  
Treatment group Body weight (g) Liver weight (g) 
Liver weight: 
Body weight ratio 
Vehicle 420.10 ± 16.19 14.69 ± 0.77 0.035 ± 0.001 
DOX 281.40 ± 9.78       10.60 ± 0.47*** 0.037 ± 0.001 
Ghrelin 408.20 ± 21.30 14.53 ± 0.94 0.036 ± 0.001 
DOX+Ghrelin 316.30 ± 7.09 12.16 ± 0.36 0.039 ± 0.001 
Results are presented as mean ± SEM (n = 7-9). *** p < 0.001 vs. vehicle. Abbreviations: DOX – 
doxorubicin g – grams vs. – versus. 
3.3 Food consumption 
In addition to monitoring body weight, the average food consumed per group was recorded 
weekly for the duration of the study. As indicated in Fig. 3.2, DOX treated animals consumed 
less food as early as the third week of treatment (144.80 g ± 3.97 g, p < 0.001) when compared to 
the vehicle group (176.00 g ± 1.37 g). This loss in appetite was maintained throughout the 
treatment protocol suggesting that DOX has appetite repressive effects. Even though the food 
consumed in the combination group (DOX+Ghrelin) did not significantly differ from the earlier 
time points, significance was obtained on the sixth (159.20 g ± 9.43 g, p < 0.05) and seventh 
(158.30 g ± 5.31 g, p < 0.05) week of treatment when compared to the DOX group (128.50 g ± 
7.27 g and 136.60 g ± 5.83 g) respectively.  
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Fig. 3.2: Average food consumption (g) recorded per week. Food consumption measurements recorded 
weekly per group following an eight week treatment regimen. Animals were treated (i.p) with saline 
(vehicle), DOX, ghrelin and a combination of the two drugs. Results are presented as mean ± SEM (n = 7-
9). ** p < 0.01, *** p < 0.001 vs. vehicle and # p < 0.05 vs. DOX. Abbreviations: DOX – doxorubicin g – 
grams vs – versus.  
 
3.4 Gross anatomy of the liver 
Once the animals were sacrificed, and the livers harvested from the various treatment groups, an 
interesting but novel phenomenon was observed. All the animals treated with DOX presented 
with significantly less lobes than all the other groups (Fig. 3.3). While the vehicle and ghrelin 
groups presented with seven lobes, the DOX treated group presented with only four lobes. The 
combination group prevented this fusion and this group presented with six lobes. Although the 
significance of this observation is currently unknown, all animals survived the treatment duration 
and thus the fusion of the lobes in the DOX group did not influence the survival.  
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Fig 3.3: Representative image of the gross anatomy of the liver. The amount of liver lobes observed 
when the animals were sacrificed and the livers harvested. Animals were treated (i.p) with saline (vehicle), 
DOX, ghrelin and a combination of the two drugs. The liver lobes are numbered 1-7. Image Resolution: 
364x2448. (n = 7-9). Abbreviations: DOX – doxorubicin.  
3.5 Liver function assessment 
3.5.1 Alanine transaminase 
The alanine transaminase (ALT) assay measures the concentration of ALT in the blood. This 
enzyme is normally found inside liver cells (hepatocytes), and when the liver is damaged or 
inflamed, ALT is released into the bloodstream in significant amounts. As the liver is also 
responsible for DOX metabolism, this study aimed to determine the influence of both DOX and 
ghrelin on liver function by utilizing different assays. Firstly, an ALT assay was used to test for 
the presence of ALT in the serum (Fig. 3.4A), however no considerable changes were observed 
between the experimental groups. Secondly, western blotting was employed to determine the 
protein expression of ALT from tissue samples (Fig. 3.4B). Although all treatment groups except 
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for the vehicle expressed more ALT, these were not statistically different from one another. 
Finally, to supplement the western blot data, staining for ALT by IHC was used (Fig. 3.4C). In 
this case, a grading system was employed either indicating a low positive or a positive result 
depending on the intensity of the brown precipitate which is indicative of ALT presence. All 
groups except for the DOX treated group were marked as low positives while the DOX group 
was marked as positive. This means that the DOX group had the most ALT present in these tissue 
samples, but since this did not leak into the blood, these results indicate that DOX did not induce 
extensive liver damage. 
 
 
 
 
 
 
 
 
Fig. 3.4A: Serum ALT concentration. ALT concentration (mU/ml) was measured in serum following 
treatment to determine liver damage. Animals were treated (i.p) with saline (vehicle), DOX, ghrelin and a 
combination of the two. Results are presented as mean ± SEM (n = 7-9). Abbreviations: DOX – 
doxorubicin.  
 
 
 
 
 
 
 
 
49 kDa 
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Fig. 3.4B: ALT protein expression detected by western blotting. Quantitative analysis of ALT 
expressed in liver tissue. The lane analysis and western blot are shown. Protein expression of ALT was 
normalized to total lane protein and the results were expressed as a percentage (%) of the vehicle. Animals 
were treated (i.p) with saline (vehicle), DOX, ghrelin and a combination of the two. Results are presented 
as mean ± SEM (n = 5-6). Abbreviations: DOX – doxorubicin kDa - kilo Daltons 
 
Figure 3.4C: Representative images of IHC detection of ALT. Animals were treated (i.p) with saline 
(vehicle), DOX, ghrelin and a combination of the two. The overall score was assigned based on the pixel 
intensity of the brown pigment. Images taken at 10x magnification (scale bar = 200 µm) (n = 3-5). 
Abbreviations: DOX – doxorubicin IHC – immunohistochemistry. 
3.5.2 Albumin 
Albumin, produced by the liver, is the most abundant protein contained in blood. Not only does 
this protein regulate colloid osmotic pressure to prevent leakage from blood vessels, it also 
DOX: Positive 
DOX+Ghrelin: Low 
iti   
Ghrelin: Low 
 
Vehicle: Low positive  
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transports essential proteins required for growth and tissue repair in the blood. Therefore, having 
a low plasma albumin level is a sign that amongst other causes either the liver or the kidneys are 
not working as they should. As demonstrated on Fig 3.5, the serum albumin levels remained 
constant throughout all experimental groups without change. Taken together, these results 
indicate that no adverse effects were induced by DOX or ghrelin on the livers capacity to 
synthesise albumin in of experimental animals. 
Fig. 3.5: Plasma albumin concentration. Albumin concentration (mg/ml) measured in the plasma. 
Animals were treated (i.p) with saline (vehicle), DOX, ghrelin and a combination of the two drugs. 
Results are presented as mean ± SEM (n = 7-9). Abbreviations: DOX – doxorubicin. 
3.6. Histological analysis of hepatic tissue 
3.6.1 Haematoxylin and Eosin (H&E) stain 
In the event of liver damage, the first structural changes that occur are the formation of non-
uniform fluid filled sacs in the cytoplasm of the hepatocytes, known as ballooning or hydropic 
changes. These are observed as micro-vesicular, if restricted to the cytoplasm with the nucleus 
intact or, macro-vesicular if they extend and displace the nucleus from its position. In this study, 
micro-vesicular ballooning (indicated with black arrows) were observed in the liver tissue 
following H&E staining (Fig 3.6). These were semi-quantified by constructing a grading system 
(Table 3.2) where the percentage hydropic changes per image of 4 lobes per rat was determined. 
An average was then calculated and grades assigned per treatment group. 
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Table 3.2: Grading system for micro-vesicular ballooning (see Appendix E, pg. 94) 
Percentage 
(%) change 
0 > 25 25 > 50 50 > 75 75 > 100 
Grade Minimal Mild Moderate Severe 
Micro-vesicular ballooning in the vehicle group was minimal as very few hydropic changes were 
observed (Fig. 3.6). While the hydropic changes seen in the ghrelin and DOX groups were 
classified as mild and moderate respectively, the ballooning in the combination group was mild 
suggesting that ghrelin may be protecting the liver against severe damage. 
 
 
 
 
 
A B 
DOX: 50% > 75% 
 
Vehicle: 0% > 25% 
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Fig. 3.6: Haematoxylin and Eosin (H&E) stain to observe structural modifications of liver tissue. 
Micro-vesicular ballooning (indicated by black arrows) in liver tissue in the various treatment groups. 
Animals were treated (i.p) with saline (vehicle), DOX, ghrelin and a combination of the two. 2-4 lobes per 
liver was analysed (n = 5-6). Images were taken at (A) 10x and (B) 20x magnification (scale bar of 200 
µm and 100 µm). Abbreviations: DOX – doxorubicin. 
 
 
 
 
 
 
DOX+Ghrelin: 25% > 50% 
 
 
Ghrelin: 25% > 50% 
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3.6.2 Masson’s trichrome stain 
When a harmful stimulus intensifies or persists, the functional liver parenchyma become replaced 
with scar tissue which consists of type I and type III collagen, as well as ground substance. This 
is known as fibrosis and can progress to cirrhosis, which is indicative of end stage liver damage. 
To evaluate potential liver damage, type I and type III collagen (indicated by the blue hue) was 
detected using the Masson’s Trichome stain in an effort to determine the presence of fibrosis. 
According to our results, this study did not observe significant fibrotic tissue in any of the 
treatments groups other than the expected type I collagen surrounding the portal triad and central 
veins, and type III collagen within sinusoids (Fig. 3.7). 
 
Fig. 3.7: Representative images of fibrosis detected by the Masson’s trichrome stain. Animals were 
treated (i.p) with saline (vehicle), DOX, ghrelin and a combination of the two drugs (n = 5-6). Images 
were taken at 20x magnification (scale bar = 100 µm). Abbreviations: DOX – doxorubicin P – portal triad 
C – central vein. 
DOX+Ghrelin Ghrelin 
P 
C 
Vehicle 
P 
DOX 
C 
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3.6.3 Reticulin stain 
Reticular fibers are a type of fiber found in connective tissue which crosslink to form a fine 
structure termed reticulin. The latter supports hepatocytes and endothelial cells that outline the 
sinusoids. The collapse or condensation of the reticulin network is indicative of a loss in 
underlying liver parenchyma. To further evaluate the effect of DOX and ghrelin on the liver, this 
study evaluated whether there is a loss of reticulin through the use of the reticulin stain (Fig. 3.8). 
Reticulin is stained as fine black lines that outline the sinusoids and the central vein and portal 
triad while the hepatocytes were stained light green. A significant reduction in reticulin is 
observed in the DOX treated group when compared to the vehicle. While ghrelin treated rats 
presented with less reticulin when compared to the vehicle, the rats treated with both DOX and 
ghrelin had more reticulin content when compared to the rats treated with DOX alone.Fig. 3.8: 
Reticulin presence in liver tissue. Representative images are taken at 20x magnification (scale bar = 100 
µm). Animals were treated (i.p) with saline (vehicle), DOX, ghrelin and a combination of the two drugs (n 
= 5-6). Abbreviations: DOX – doxorubicin. 
Vehicle  DOX  
Ghrelin  DOX+Ghrelin  
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3.6.4. Periodic Acid Schiff (PAS) stain. 
The liver plays an integral role in metabolism and stores glucose in the form of glycogen. While 
ghrelin has previously been found to promote the release of glucose from the liver, literature does 
not report on the effect of DOX in this context. The Periodic Acid Schiff stain was therefore used 
to detect glycogen content (indicated by the magenta hue) in all treatment groups (Fig. 3.9A), and 
this was quantified with the grey scale threshold on Image J software (Fig.3.9B). Based on our 
results, the glycogen content remained the same throughout the treatment groups with no major 
differences observed. This means that both DOX and ghrelin did not affect the amount of 
glycogen present in the liver. 
 
Fig. 3.9A: Periodic Acid Schiff stain detects glycogen in liver tissue. Representative images were taken 
at 20x magnification (scale bar = 100 µm). Animals were treated (i.p) with saline (vehicle), DOX, ghrelin 
and a combination of the two drugs (n = 5-6). Abbreviations: DOX – doxorubicin  
Vehicle  Ghrelin  
DOX  DOX+Ghrelin 
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Fig. 3.9B: Quantification of glycogen content detected by the Periodic acid Schiff stain. The average 
percentage glycogen content was quantified with the grey scale threshold on the Image J software. 
Animals were treated (i.p) with saline (vehicle), DOX, ghrelin and a combination of the two drugs. 
Results are presented as mean ± SEM (n = 5-6). Abbreviations: DOX – doxorubicin. 
 
3.6.5 Oil Red O stain 
A fatty liver is a reversible condition where large vacuoles of triglyceride fat accumulate in liver 
cells via a process known as steatosis. This occurs as a result of disturbances in fat metabolism 
which causes excessive accumulation of fat in the liver. While the effects of DOX on fat 
accumulation in the liver are currently unknown, ghrelin promotes lipid accumulation within 
liver tissue and can result in lipotoxicity if the accumulation is severe. This study evaluated fat 
accumulation by performing an Oil Red O stain on frozen liver tissue samples (Fig. 3.10). The 
hepatocytes stain a purple/blue colour, whereas the lipid droplets within hepatocytes stain red. 
The lipid content within the tissues was determined by infrared-based quantitation (Table 3.3). 
Our findings reveal that while DOX reduced lipid accumulation, ghrelin significantly (0.13 ± 
0.009 AU, p <0.001) increased lipid accumulation when compared to the vehicle (0.05 ± 0.003 
AU). The result found that lipids in the DOX+Ghrelin experimental group were similar compared 
to the DOX group.  
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Fig. 3.10: Oil Red O stain for the detection of fat accumulation in liver tissue. Representative images 
were taken at 20x magnification (scale bar = 100 µm). Animals were treated (i.p) with saline (vehicle), 
DOX, ghrelin and a combination of the two drugs (n = 5-6). Abbreviations: DOX – doxorubicin.  
Table 3.3: Relative lipid content present in hepatic tissue 
Group Vehicle DOX Ghrelin DOX+Ghrelin 
Lipid absorbance 
 (AU) 
0.05 ± 0.003 0.03 ± 0.009 0.13 ± 0.009*** 0.04 ± 0.004 
Results are presented as mean ± SEM (n = 3-5). *** p < 0.001 vs. vehicle. Abbreviations: DOX – 
doxorubicin, AU - arbitrary units, vs. - versus. 
DOXVehicle
DOX+GhrelinGhrelin
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3.7. Oxidative Stress 
3.7.1 Lipid Peroxidation 
DOX induced toxicity on healthy tissues is mainly as a result of the production of ROS creating a 
condition of oxidative stress when the anti-oxidant systems become overwhelmed. As ghrelin has 
been found to possess anti-oxidative properties, this study evaluated oxidative stress indirectly by 
assessing lipid peroxidation. Although ROS have a short half-life, they oxidize cellular 
membranes to produce conjugated dienes (CDs) (early marker) that are converted to 
malondialdehyde (MDA) (late marker). As indicated in Fig. 3.11, no significant differences were 
observed in either CDs or MDA content in the liver tissue.  
 
 
 
 
 
 
 
 
 
Fig. 3.11: Lipid peroxidation of rat liver tissue. Markers for lipid peroxidation were assessed by 
measuring conjugated diene (umol/g) (A) and malondialdehyde (µmol/g) (B) content as early and late 
markers respectively. Animals were treated (i.p) with saline (vehicle), DOX, Ghrelin or DOX+Ghrelin. 
Results are presented as mean ± SEM (n = 5-6). Abbreviations: DOX – doxorubicin. 
 
3.7.2 Anti-oxidant status 
To supplement the lipid peroxidation data, the anti-oxidant status of liver tissue was examined. 
Glutathione is the most significant non-enzymatic oxidant defence system. It undergoes a redox 
reaction where reduced glutathione (GSH) neutralizes free radicals through donating an electron, 
resulting in the rise of oxidized glutathione (GSSG). Due to the rapid nature of the formation of 
GSSG relative to synthesis or secretion of GSH, the ratio of GSH to GSSG is a good indicator of 
oxidative stress (Table 3.4). The results obtained in this experiment echoed those observed for 
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oxidative damage where no considerable changes were detected. This was rather surprising due 
to the known ROS producing effects of DOX, as well as the high iron content within this tissue. 
 
Table 3.4: Glutathione analysis of rat liver tissue 
Treatment group GSH (umol/g) GSSG (umol/g) GSH:GSSG 
Vehicle 1.52 ± 0.39 0.45 ± 0.10 1.53 ± 0.08 
DOX 1.68 ± 0.34 0.33 ± 0.02 1.48 ± 0.19 
Ghrelin 1.95 ± 0.19 0.37 ± 0.04 1.58 ± 0.20 
DOX+Ghrelin 1.99 ± 0.20 0.39 ± 0.04 1.60 ± 0.23 
 
Results are presented as mean ± SEM (n = 5-6). Abbreviations: DOX – doxorubicin g – grams. 
 
3.8. Autophagy, Apoptosis and Endoplasmic Reticulum (ER) Stress 
Despite the controversies in the literature regarding the effects of DOX on autophagy, this 
process contributes to the regulation of hepatic lipid metabolism by facilitating the degradation of 
lipid droplets to sustain energy homeostasis during energy exhaustion. p62 degradation and LC3 
lipidation are two major hallmarks of autophagy execution. Our results show a decrease in the 
protein expression of p62 and an increase in LC3-II in all treatment groups when compared to the 
vehicle (Fig. 3.12). This is suggestive of elevated autophagic activity and increased flux through 
this pathway.  
There are numerous reasons why autophagy in this context may be elevated. Firstly, autophagy 
may be induced as a result of oxidative stress; however since oxidative stress was not detected in 
this study, autophagy may be induced to prevent apoptosis from taking place. This study shows 
that both cleaved caspase-3 and cleaved PARP were upregulated by DOX and ghrelin alone 
versus the vehicle (Fig. 3.13). However, DOX treatment in the presence of ghrelin reduced the 
protein expression of these apoptotic proteins when compared to the DOX group. This result 
exemplifies ghrelin’s anti-apoptotic effects.  
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Interestingly, apoptosis and autophagy in this context may be induced as a result of ER stress, a 
condition that arises when there is an accumulation of misfolded proteins or a depletion of the ER 
calcium stores. In response to this stress, the UPR is triggered to limit protein synthesis and to 
initiate protein degradation via ERAD (endoplasmic associated degradation). This study 
demonstrates that under basal conditions, the liver presents with relatively elevated levels of ER 
stress as indicated by the increased expression of BiP and AFT4 (Fig. 3.14). Similar observations 
were seen in the ghrelin group. Although DOX reduced BiP and ATF4 when compared to the 
vehicle, the DOX+Ghrelin group maintained elevated levels of ATF4 when compared to the 
DOX treated group. 
 
Fig. 3.12: Relative protein expression of p62 and LC3 in hepatic tissue determined by Western 
blotting. Abbreviations: DOX – doxorubicin LC3 - microtubule associated protein 1 light chain 3 kDa - 
kilo Daltons. 
 
Fig. 3.13: Relative protein expression of cleaved caspase-3 and cleaved PARP in hepatic tissue 
determined by Western blotting. Abbreviations: DOX – doxorubicin PARP - Poly (ADP-ribose) 
polymerase kDa - kilo Daltons. 
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Fig. 3.14: Relative protein expression of BiP and ATF4 in hepatic tissue determined by Western 
blotting. Abbreviations: DOX – doxorubicin BiP - binding immunoglobulin heavy chain-binding protein 
ATF4 - Activating Transcription Factor 4 kDa - kilo Daltons.  
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Chapter 4 
________________________________________________________________ 
Discussion 
This study set out to determine the effects of DOX, a potent chemotherapeutic agent, on the liver 
using a chronic model of DOX-induced cardiotoxicity. As there is no cure for this disease, 
current research is aimed at identifying therapeutic interventions that counteract the damaging 
effects of this anti-cancer regimen. Ghrelin, a brain-gut peptide, known for its appetite inducing 
effects has previously been shown to possess anti-oxidant, anti-apoptotic, anti-fibrotic and anti-
inflammatory effects, all of which contributes to the development of cardiotoxicity. While 
literature has mainly focused on cardiovascular injury induced by DOX, few studies has paid 
attention to the liver which is responsible for DOX’s metabolism and exit out of the body. The 
model used in this study simulated long-term dose-dependent toxicity often observed in patients 
who develop adverse cardiovascular complications following DOX therapy. Therefore, the 
cumulative DOX concentration (20 mg/kg) provided to the experimental animals fell within the 
range of 60 - 75 mg/m2 that is administered to humans (human equivalent dose) (Desai et al., 
2013; Von Hoff et al., 1979). In addition, the age of the animals at the start of the study was 
taken into consideration. Experimentation began when animals were five weeks old which 
indicates a young age, and by the time the study was concluded, the animals were 13 weeks old 
which is comparable to adulthood in humans. Finally, since cardiotoxicity takes some time to 
manifest, usually when cancer has been treated or in remission, it is for this reason that cancer 
was not induced in this module before treatment commenced. 
4.1 Ghrelin promotes food consumption and prevents severe body weight loss 
A well-known side effect of chemotherapeutic agents including DOX, is the loss of appetite 
resulting in weight loss (Kalender et al., 2005). Severe weight loss reduces a patient’s quality of 
life and limits the dose and the duration of a potential curative treatment. Therefore, appetite 
stimulants such as ghrelin provide an advantage towards the prevention of weight loss and the 
improvement of a patient’s nutritional status (Neary et al., 2004). This study demonstrated 
reduced weight gain in the animals that received DOX treatment (Fig. 3.1) and this was caused 
by a reduction in the food consumed by these animals (Fig. 3.2). Although the animals that 
received both treatment regimens ate significantly more food when compared to the DOX group, 
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this effect was not reflected in the body weight data as expected. Rodents are small animals that 
have a higher surface-to-volume ratio, and thus lose relatively larger heat loss to the environment 
per unit in time. In an effort to maintain body temperature despite rapid heat loss, these animals 
oxidize food at an elevated rate (Glider, 2011). This study therefore proposes that due to the 
appetite repressive effects of DOX, as well as the high metabolic rate of these animals, the food 
consumed was metabolised and immediately used to maintain normal physiological functions 
instead of it being stored. In support of our observations, numerous studies have shown decreased 
weight gain and food consumption due to DOX treatment (Wang et al., 2014; Injac et al., 2009), 
whereas others have demonstrated increased appetite and subsequent food intake after exogenous 
ghrelin administration independently of GH secretion (Wren et al., 2000, Neary et al., 2004).  
It was expected that treatment with ghrelin alone would induce a potent increase in food intake, 
however this effect was not observed in this study. In a similar manner, Shintani and colleagues 
(2001) illustrated a significant increase in food intake four hours following ghrelin 
administration, but this effect was lost after 24 hours. Increased food intake following ghrelin 
administration is said to occur within 60 mins in rodents, which means that daily (24 hours) 
monitoring of food intake can be missed. Even though ghrelin’s orexigenic effects are indicated 
to be more powerful when ghrelin is administered centrally (intra-cerebroventricular), rather than 
peripherally (i.p), ghrelin does not regulate energy homeostasis directly (Wren et al., 2000). 
Instead, ghrelin increases the expression of NPY and AgRP neurons which co-localize with 
GHS-R1α in the arcuate nucleus in the nutrient centre of the brain, and by stimulating 
glycogenolysis and gluconeogenesis in hepatocytes (Leite-Moreira & Soares, 2007) and the 
promotion of genes that favour lipogenesis and triglyceride storage in the liver (Barazonni et al., 
2005). 
4.2 DOX induces fusion of hepatic tissue 
The liver regulates its mass in response to body weight. The optimal liver to body weight ratio is 
reached when the liver performs the amount of metabolic work required for the body to function 
optimally (Fausto, 2000; Michalopoulos & DeFrances, 1997). This organ will either proliferate to 
increase its mass in response to body weight gain or undergo apoptosis in response to body 
weight loss (Fausto, 2000; Wang et al., 2014). In this study there were no changes among the 
treatment groups when liver weight was expressed relative to body weight (Table 3.1). Although 
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ghrelin administration with DOX treatment did not significantly alter liver mass, additional loss 
of liver mass was inhibited. 
 
As mentioned previously, the liver is divided into median, right, left and caudate lobes. The 
median, right and caudate lobes are further subdivided into two more parts, giving the appearance 
that rat liver has seven lobes (Malarkey et al., 2005). In this study the morphological appearance 
of the rat liver in the vehicle and ghrelin treatment groups presented with seven lobes (Fig. 3.3), 
while those that were treated with DOX only presented with four lobes (except for one out of the 
nine animals in this group), which is suggestive of fusion. Interestingly, this fusion of liver lobes 
was not prominent in the animals co-treated with DOX and ghrelin as they presented with six 
lobes. To the best of our knowledge, this novel observation has not previously been reported and 
further implies that ghrelin impedes this fusion. While this observation may infer a protective 
effect by ghrelin, all animals survived the treatment duration and therefore the significance of 
these results warrant further investigation. 
As mentioned previously, DOX administered intraperitoneally versus intravenously, has a 40% 
bioavailability and remains in the abdominal cavity for an extended period (Nagai et al., 2013). 
In addition, in the clinical setting DOX administered intraperitoneally to treat patients with 
ovarian cancer has resulted in peritoneal irritation (Ozols et al., 1982). In our study, peritoneal 
irritation with intestinal adhesions was observed when the rats were sacrificed. Therefore, this 
study proposes that DOX administration via i.p injection possibly initiated peritoneal irritation 
where the corrosive property of DOX eroded the Glisson capsule surrounding the liver, and 
induced tissue injury that led to the fusion of adjacent lobes. The standard response to tissue 
injury in all mammalian organ systems is to prevent blood loss (Gurtner et al., 2008). A platelet 
plug is initially formed to arrest bleeding from breached blood vessels to signal blood 
coagulation. Once bleeding has been stopped and tissue healing occurs, the plug is removed 
through a process termed clot retraction. The platelets within the clot contract and pull the edges 
of the damaged vessels together (Sherwood, 2013). Therefore, erosion of the Glisson capsule 
exposes hepatocytes of adjacent lobes to one another and through coagulation and clot retraction, 
hepatic fusion ensues. An important factor to be considered in this scenario is the fact that 
treatment began when the animals were at a relatively young age where the liver was still in a 
process of growth and development, and it is likely that DOX impaired these processes. Finally, 
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since the liver is a regenerative organ that can undergo partial hepatectomy, where two thirds of 
the liver can be removed; this organ is able to regenerate with the remaining lobes enlarging to 
compensate for the loss of liver mass. However, the lost lobes never grow back, and the livers are 
able to function normally with less lobes (Michalopoulos & Defrances, 1997). It should also be 
noted that the lobes of a rat liver has different susceptibilities to toxicity depending on the agent 
being used. For example, rats treated with dimethylnitrosamine had more damage in the left and 
left median lobes compared to the rest of liver lobes. Similary, carbon tetrachloride induced 
greater damage in the right lobes compared to the left lobes. These effects were observed 
independent of the route of administration (Lawson and Pound, 1974).  
 
4.3 DOX treatment does not impair liver function  
ALT is highly expressed in the liver where it plays a fundamental role in gluconeogenesis and 
amino acid metabolism (Reagan et al. 2012). Injury to the liver results in the release of ALT into 
the serum. Thus, elevated serum ALT is an indication of liver damage. Although ALT is largely 
localized in the liver, it is also expressed in other tissue types including muscle, heart and 
digestive tract (Giannini et al., 2005). While hepatotoxicity induced by DOX therapy has 
previously been shown in vivo (Swamy et al., 2012) and clinically (Damodar et al., 2014), this 
study did not demonstrate differences in ALT between the groups (Fig. 3.4). The major 
difference between these studies was the frequency and duration at which DOX was 
administered. Whereas at this current study administered DOX once weekly for eight weeks, 
Swamy and colleagues (2012) injected DOX six times over a period of two weeks to make a 
cumulative dose of 15 mg/kg. Although our study administered a higher cumulative dose (20 
mg/kg) over time, the frequency at which DOX was administered may have accounted for the 
differences observed. A similar result was also obtained for plasma albumin where no changes 
were observed (Fig. 3.5). Albumin is exclusively produced by the hepatocytes and a decrease in 
circulation is indicative of not only liver damage (Thapa & Walia, 2007) but also nephrotoxicity 
and protein losing enteropathies. A marked reduction in albumin synthesis has been demonstrated 
in DOX treated animals following hepatic resection which coincided with necrosis of hepatocytes 
not observed in this study (Tanaka et al., 1982). Like other studies, the frequency and duration of 
DOX treatment differed. It can thus be concluded that while treatment with DOX is toxic to the 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 59 
 
liver, where toxicity is dependent on frequency and duration of treatment, over time this organ 
can regenerate and heal itself once the harmful stimulus is prevented.  
 
4.4 DOX and ghrelin induce minor structural changes in liver histology  
When the liver is damaged, one of the first structural changes that occurs is ballooning, also 
known as hydropic changes. Hepatocyte ballooning indicates the presence of a non-uniform fluid 
filled sac found in the cytoplasm of the hepatocytes. Literature reports that ballooning arises due 
to: (i) damage of hepatocyte membranes that allows entry of sodium into a cell with osmotically 
obliged water, or (ii) a lack of ATP to furnish the energy required for the sodium pump to 
function optimally, and thereby allows excess sodium and water to accumulate (Edmondson et 
al., 1967). It could also occur due to cytoskeletal alterations where keratin 8 and 18 are disrupted 
and no longer spread throughout the cytoplasm (Takahashi et al., 2014). While DOX and ghrelin 
demonstrated moderate and mild hydropic changes respectively, the co-administration of DOX 
and ghrelin together showed mild ballooning (Fig. 3.6). Our results are in stark contrast to the 
literature where structural changes have not been observed as a result of ghrelin treatment. The 
reason for this could be the fact that this study utilised a higher ghrelin concentration (300 
µg/kg/week) than Li et al. (2013) and Cetin et al. (2011) who administered lower ghrelin 
concentrations of 30 ng/kg/week and 50 ng/kg/week respectively. 
When a harmful stimulus is chronically persistent and occurs frequently enough, scarring occurs 
and liver parenchyma are replaced with collagen in a phenomenon termed fibrosis. Fibrosis can 
progress to cirrhosis which is indicative of end stage liver damage. A cirrhotic liver lacks normal 
hepatic lobules and the hepatocytes are enclosed in a fibrotic circle, also termed a nodule 
(Anthony et al., 1978). Hepatic fibrosis is characterized by an increase in extracellular matrix 
constituents that include type I and type III collagen forming a hepatic scar (Friedman, 1993). 
Since normal type I and type III collagen are naturally found around the portal triad, central vein 
and sinusoids, care should be taken not to term blue staining (Masson Trichome) in these areas as 
fibrotic tissue (Lefkowitch et al., 2006; Murli, 2013). No prominent fibrosis was observed in this 
study other than where it was expected (Fig. 3.7). This could be attributed to the limitation of our 
light microscopic observations but also the frequency of DOX treatment as observed by others 
(El-Sayyad et al., 2009). 
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Reticulin, composed of type II collagen, is found within the extracellular matrix of the space of 
Disse outlining the sinusoids. It functions to support hepatocytes and endothelial cells outlining 
the hepatocytes (Krishna, 2013). The loss or condensation of reticulin signals the loss of 
underlying liver parenchyma and also used in the diagnosis of fatty liver disease (Lefkowitch, 
2006; Dixon et al., 2001).This study illustrates a significant loss of reticulin in the liver of the rats 
treated with DOX and this was not recovered by ghrelin adjuvant therapy (Fig. 3.8). In fact, 
ghrelin itself reduced reticulin expression and this result may imply a degree of toxicity. A loss of 
reticulin is an indication of fat accumulation, and in this study ghrelin treatment alone resulted in 
a significant fat accumulation. DOX treatment did not result in fat accumulation, hence, the loss 
of reticulin as a result of DOX treatment should further be investigated. Although studies 
evaluating the effects of DOX on reticulin expression in the liver are rare, the use of reticulin 
stain has been found to be valuable mainly in the differential identification of well-differentiated 
hepatocellular carcinoma and benign hepatic nodules (Hong et al., 2011). 
4.5 Ghrelin promotes fat accumulation and not glycogen storage in the liver 
The liver is the second largest organ to store glycogen in the body and consequently supplies 
glucose in the event of low circulating levels (Campbell, 2006b). Several studies have reported 
that ghrelin promotes glucose release from hepatocytes by upregulating the activity of the 
enzyme glucose-6-phosphatase (Gauna et al., 2005; Barazonni et al., 2005). No changes in 
glycogen content within hepatocytes in this study was observed (Fig. 3.9). Additionally, the liver 
is involved in lipid metabolism through the incorporation of fatty acids into complex lipids such 
as triglycerides. These are further assembled into lipoproteins to be transported into circulation. 
Although lipids are stored subcutaneously or in adipose tissue, they may accumulate in vital 
peripheral organs such as the liver. This ectopic fat has been associated with the development of 
non-alcoholic fatty liver disease (NAFLD) and insulin resistance (Griffin, 2013). By reducing the 
activity of AMPK, a potent inducer of fatty acid oxidation (Barazonni et al., 2005), exogenous 
ghrelin administration has been found to reduce fat utilization and promote fat storage (Tschöp et 
al., 2000). Similar observations were made in this study as ghrelin treatment increased fat 
storage, while DOX amplified its utilization resulting in its reduction (Fig. 3.10). Considering 
that the liver utilizes free fatty acids as an energy source (Zámbó et al., 2013), this may have 
accounted for the reduced lipid accumulation when both treatments were combined. 
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4.6 DOX does not induce oxidative damage or changes in antioxidant status 
DOX is well known for its stimulatory oxidative properties which induces oxidative damage to 
healthy tissues. The ROS generated oxidizes lipid structures of organelles and cellular 
membranes, resulting in conjugated dienes and malondialdehydes which are markers of lipid 
peroxidation (Jafari et al., 2007; Gutteridge, 1995; Halliwell & Chirico, 1993). Even though lipid 
peroxidation has been observed following DOX treatment (Kalender et al., 2005, Pieniążek et al., 
2013; Wang et al., 2014), the current study did not observe any considerable changes in the 
different experimental groups (Fig. 3.11). Unlike the heart, the liver has superior antioxidant 
levels and operates at a lower oxidative environment (Carvalho et al., 2009), and is thus not 
prone to oxidative damage unless it is severe. Glutathione is produced in the cytoplasm of 
hepatocytes and from here, it is distributed to the rest of the bodily tissues. Mainly present in two 
forms, glutathione is reduced following oxidation to form GSSG from GSH (Arrick & Nathan, 
1984). GSH plays a vital role in ROS scavenging and the detoxification of drugs and toxins, and 
therefore a decrease in the ratio of GSH to GSSG is suggestive of oxidative stress (Jafari et al., 
2007). Our findings regarding glutathione status (Table 3.4) echoed those observed for lipid 
peroxidation. Despite our non-significant findings, ghrelin is a potent inducer of antioxidant 
enzyme activity such as glutathione reductase, which catalyses the conversion of GSSG back to 
GSH (Dobutovic et al., 2014; Couto et al., 2016).  
 
4.7 Ghrelin prohibits DOX-induced cell death 
Apoptosis is one of the hallmarks of DOX-induced toxicity and has been observed to occur in 
liver tissue following DOX administration (Wang et al., 2014). It can occur via two mechanisms; 
intrinsically as a result of cytochrome c leakage from mitochondria (Owe et al., 2008), or 
extrinsically due to the presence of inflammatory cytokines (Gustaffson and Gottlieb, 2003; Hsu 
et al., 1995). These pathways initiate the caspase cascade converging at caspase-3 which cleaves 
PARP. PARP functions to repair oxidatively damaged DNA but when cleaved by caspase-3, the 
cell will resort in apoptotic cell death. As expected, DOX induced significant apoptosis as 
demonstrated by the increased presence of caspase-3 and PARP cleavage (Fig. 3.13). While 
ghrelin is known to be anti-apoptotic (Lee et al., 2016), this effect was only observed when DOX 
treatment was provided in combination with ghrelin. The manner in which this happens is the 
prevention of cleavage of pro-apoptotic proteins, but also through the phosphorylation and 
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activation of serine/threonine kinase Akt (PKB) and extracellular signal-regulated protein kinases 
1 and 2 (ERK1/2) (Baldanzi et al., 2002). Together, these findings propose that ghrelin inhibits 
apoptosis by modulating the stress-induced apoptotic signalling pathways. 
Autophagy is known as a double edged sword as its activation may be protective or detrimental 
depending on the stimulus and the context of which it is studied (Dirks-Naylor, 2013; 
Kawagachu et al., 2012). This process removes damaged proteins or organelles from cells and the 
by products are then recycled for energy production. In the context of DOX toxicity, autophagic 
activity is controversial as some studies demonstrate elevated activity (Smuder et al., 2013; Lu et 
al., 2009), while others show reduced activity (Sishi et al., 2013b; Kawagachu et al., 2012). 
Autophagic degradation begins with the formation of an isolation membrane (phagophore) that 
sequesters cytoplasmic components into double membraned autophagosomes. These 
autophagosomes fuse with lysosomes containing digestive enzymes where the autophagosomal 
cargo is degraded (Mizushima, 2007). To date, only LC3 has been acknowledged as an 
autophagosomal inner membrane protein that serves as a receptor for p62/SQSTM1 (sequestome 
1), an adapter protein with ubiquitin-binding domains, which is selectively degraded by 
autophagy (Bjørkøy et al., 2005). This study demonstrates that both DOX and ghrelin induced 
autophagic activity as p62/SQSTM1 expression was reduced, suggesting degradation, and LC3-I 
was converted LC3-II (Fig. 3.12). Since autophagy is accompanied with other forms of cell death 
such as apoptosis, it is often challenging to discern whether it is pro-death or pro-survival 
(Kobayashi et al., 2010). Thus, autophagy and apoptosis can act together to cause cell death or, 
autophagy can inhibit apoptosis by acting as an antagonist to promote survival or, autophagy may 
enable apoptosis by permitting apoptosis to take place without resulting in death by autophagy 
(Eisenberg-Lerner et al., 2009). Autophagy in this context may also be upregulated to assist 
proteasomal degradation, as it has previously been demonstrated to be obstructed by DOX 
molecules which hijack its activity to gain entry into the nucleus (Fekete et al., 2005; Kiyomiya 
et al., 2002). 
The proteasome is a constituent of the ubiquitin-proteasome pathway, a major bulk degradation 
system contained in all mammalian cells. It functions to remove long-lived, damaged or 
misfolded proteins in an ATP- and ubiquitin-dependent manner. Protein folding mainly takes 
place within the ER and when disturbances in the REDOX status and ER folding capacity occur, 
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ER stress is triggered due to the build-up of these misfolded proteins within the ER lumen. In 
response to this stress, the UPR is initiated to relay formation about the degree of protein folding 
capacity from the rough ER to other cellular locations. In this regard, activation of the UPR 
momentarily mitigates the rate of protein synthesis and increases genes responsible for encoding 
chaperones, ER-associated degradation (ERAD) proteins,  ER membrane biogenesis enzymes  
and autophagy regulators (Hetz et al., 2008). Essentially, the UPR signalling pathway reduces the 
build-up of misfolded proteins by amplifying the functional capacity of the ER to promote 
folding and to eradicate abnormal proteins. This study demonstrated a stark difference in the 
effect of both DOX and ghrelin on UPR activation (Fig. 3.14). While an expected basal level of 
UPR activity was observed in the control group which was maintained by ghrelin, DOX 
downregulated activation of this signalling pathway, whereas both treatments together sustained 
relative activity. Literature however does not support our observations as DOX is known to 
induce ER stress due to disruptions in calcium homeostasis and calcium receptors either located 
on the ER (Mitry et al., 2016) or mitochondria (Zhou et al., 2001). It is thus plausible to 
speculate that the effect of DOX on ER stress may be tissue specific in much the same way as its 
toxic effects are different from its anti-neoplastic activity. 
In conclusion, this study demonstrates that the liver is a robust organ that can withstand a great 
deal of stress and toxicity as weekly administration of DOX did not induce severe liver damage. 
While liver morphology was altered by DOX, structural parameters measured and function tests 
remained unchanged. No adverse oxidative damage was observed, nor was there any variation in 
the anti-oxidant status of this tissue. Molecularly, ghrelin reduced caspase-3 cleavage and 
increased p62 degradation and LC3-II protein expression. Therefore, while ghrelin’s protective 
effects were mainly observed as a result of its orexigenic properties, its effect against DOX on the 
liver requires further investigation. 
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Chapter 5 
5.1 Limitations 
The major limitation in this study was the fact that this only had one time point of analyses. 
Additional time points would add value to the study in order to determine the very early changes 
that may have been induced by either DOX, ghrelin or both treatment regimens. 
 
5.2 Future directions 
• To further investigate the cause of liver lobe fusion due to DOX treatment. 
• To evaluate the potential role of reticulin in liver lobe fusion. 
• To determine the extent of the inflammatory response in this context. 
• Due to the fact that the liver is a highly metabolic organ with numerous mitochondria, 
mitochondrial dynamics should be assessed to better understand the relative molecular 
changes that take place within this organ as a result of DOX and ghrelin treatment. 
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Appendix A 
___________________________________________________________________ 
Normalization graphs for western blot and loading controls 
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Fig. 4.1:  Normalization of relative protein expression of p62 (A) and LC3-II (B).  The lane 
analysis is shown where protein expression of p62 and LC3-II was normalized to total lane protein and 
the results are expressed as a percentage (%) of the vehicle. Animals were treated (i.p) with saline 
(vehicle), DOX, ghrelin and a combination of the two. Results are presented as mean ± SEM (n = 5-6).  
Abbreviations: DOX – doxorubicin  
Ve
hic
le
DO
X
Gh
rel
in
DO
X+
Gh
rel
in
0
50
100
150
200
250
Cl
ea
ve
d 
PA
RP
 p
ro
te
in
 e
xp
re
ss
io
n 
as
 a
 p
er
ce
nt
ag
e 
(%
)
of
 th
e 
ve
hi
cl
e
Fig. 4.2: Normalization of relative protein expression of cleaved PARP. The lane analysis is shown 
where protein expression cleaved PARP was normalized to total lane protein and the results are 
expressed as a percentage (%) of the vehicle. Animals were treated (i.p) with saline (vehicle), DOX, 
ghrelin and a combination of the two. Results are presented as mean ± SEM (n = 5-6).  Abbreviations: 
DOX – doxorubicin  
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Fig. 4.3: Normalization of relative protein expression of cleaved caspase 3 (A) 19 kDa (B) 17 
kDa. The lane analysis are shown where protein expression of cleaved caspase 3 (19 kDa and 17 kDa) 
was normalized to total lane protein and the results are expressed as a percentage (%) of the vehicle. 
Animals were treated (i.p) with saline (vehicle), DOX, ghrelin and a combination of the two. Results 
are presented as mean ± SEM (n = 3-5).  Abbreviations: DOX – doxorubicin  
  
  
  
Fig. 4.4: Normalization of relative protein expression of BiP (A) and ATF4 (B). The lane analysis 
are shown where protein expression of BiP and ATF4 was normalized to total lane protein and the 
results are expressed as a percentage (%) of the vehicle. Animals were treated (i.p) with saline 
(vehicle), DOX, ghrelin and a combination of the two. Results are presented as mean ± SEM (n = 5-6).  
Abbreviations: DOX – doxorubicin  
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Fig. 4.5: Loading controls for the western blots. Membrane activation which indicates loading 
control for the western blot bands where (A) Cleaved caspase 3 (B) Cleaved PARP (C) p62 (D) LC3-I 
and LC3-II and (E) BiP and ATF4 
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Appendix B 
___________________________________________________________________ 
Ethical clearance letter for animal study. 
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Appendix C 
________________________________________________________________ 
Preparation of DOX and ghrelin for animal treatment 
DOX was prepared as follows:  
50 mg DOX (LKT Laboratories, D5794, USA) in 12.5 ml sterile saline to give a stock solution of 
4 mg/ml = 4 µg/µL. This solution was vortexed thoroughly.  
Animal dose = 2.5 mg/kg = 2.5 µg/g 
Example: Animal weight = 118.1 g 
118.1 g x 2.5 µg/g 
295.25 µg DOX 
Stock = 4µg/µL 
4 𝜇𝜇𝜇𝜇
1 𝜇𝜇𝜇𝜇 = 295.25 𝜇𝜇𝜇𝜇𝜒𝜒   
Χ = 73.8125 µL DOX stock (4 µg/µL) and add sterile saline to create a total volume of 200 µl 
(200 µL is the injection volume)  
BUT…multiply by 2 to account for bubbles and wastage.  
 73.8125 x 2 = 147.625 µL DOX in 253.375 µL saline  
Vortex thoroughly  
Inject 200 µL 
Ghrelin was prepared as follows: 
5 mg ghrelin (LKT Laboratories, G2869, USA) was suspended in 5 mL sterile saline to give 
stock solution of 1 mg/mL = 1 µg/µL. This solution was vortexed thoroughly.  
Animal dose: 100 µg/kg = 0.1 µg/g 
Example: Animal weight: 118.1 g 
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118.1 x 0.1 µg/g  
11.81 µg ghrelin 
Stock = 1 µg/µL 
1 𝜇𝜇𝜇𝜇
1 𝜇𝜇𝜇𝜇 = 11.81 𝜇𝜇𝜇𝜇𝑥𝑥   
Χ = 11.81 µL of ghrelin stock solution and add sterile saline to create a total volume of 200 µl 
(200 µL is the injection volume)  
BUT…multiply by 2 to account for bubbles and wastage 
Inject 200 µL  
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Appendix D 
________________________________________________________________ 
Liver function tests 
Protocol 1: Alanine transaminase activity assay  
Alanine Transaminase Activity Assay Kit (colorimetric/Flouremnitric) (Abcam, ab105134, SA) 
was used for the detection of ALT in the serum.  The colorimetric assay was executed according 
the manufacturer’s instructions.  
Reagent and sample preparation 
1. Thaw the serum on ice
2. The ALT assay buffer is ready to use as supplied. Equilibrate to room temperature before
use.
3. Oxired probe warmed at 37ᵒC for 1-5 minutes to thaw the DMSO in the solution.
4. Reconstitute the ALT enzyme mix with 220 µl distilled water and keep on ic e while in
use.
5. Reconstitute the ALT substrate with 1.1 ml Assay buffer and keep on ice while in use.
6. Pyruvate standard is ready to use as supplied and keep on ice while in use.
7. Reconstitute the ALT positive control with 100 µl of distilled water and keep on ice while
in use.
Assay procedure and detection 
1. Prepare a standard to run with the samples:
a. Prepare a 1 nmol/µl Pyruvate Standard by diluting 5 µl Pyruvate standard in 495
µl of ALT assay buffer .
b. Use the 1 nmol/µl Pyruvate Standard to prepare the standard curve dilution as
described in the table below:
Standard # Volume of 
standard (µl) 
Assay Buffer 
(µl) 
Final Volume 
standard in well 
Concentration of 
ALT in well 
(nmol/well) 
1 0 60 20 0 
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2 6 54 20 2 
3 12 48 20 4 
4 18 42 20 6 
5 24 36 20 8 
6 30 30 20 10 
2. Set up the reactions wells in clear 96 well plate.
a. Standard wells = 20 µl of a standard dilution. The standards should be tested in
triplicate.
b. Sample wells = 2-20 µl sample and then adjust the volume to 20 µl with the ALT
assay buffer.  Sample should be tested in duplicate or triplicate
c. Positive control = 5-10 µl positive control in a well and then adjust the volume to
20 µl with the ALT assay buffer.
3. Prepare the reaction mixture as described in the table below. Prepare 100 µl of reactioin
mix per well. Thus, prepare a master mix of the reaction mix for the amount of standards,
positive control and samples tested.  This will ensure consistency.
Component Colorimetric reaction mix (µl) 
ALT assay buffer 86 
Oxired probe 2 
ALT enzyme mix 2 
ALT substrate 10 
4. Add 100 µl of the reaction mix into each well of standard, sample and positive control.
5. Measure the absorbance on a microplate reader (BMG Labtech, SPECTROstar nano,
Germany)  at 570 nm in a kinetic mode after 10 minutes, every 2 - 3 minutes, for atleast
60 minutes at 37˚C protected from light.
Processing of the results 
1. Average the duplicate/triplicate reading for each standard and sample.
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2. Subtract the mean absorbance value of the blank (standard #1) from all standard and
sample readings.
3. Plot the corrected absorbance values for each standard as a function of the final
concentration of pyruvate.
4. Draw the best smooth curve through these points to construct the standard curve.
Calculate the trendline equation based on your standard curve data (use the equation that
provides the most accurate fit).
5. Calculate the ALT activity for your samples with the following equation:
∆𝐴𝐴570 𝑛𝑛𝑛𝑛 =  𝐴𝐴2 − 𝐴𝐴1 
Where: 
A1 is the sample reading at the T1 
A2 is the sample reading at the T2 
6. Then use the ΔA570 nm to obtain the B nm of pyruvate generated by ALT during the
reaction time (ΔT = A2 – A1).
7. The concentration of pyruvate in the test sample is calculated as:
𝐴𝐴𝐴𝐴𝐴𝐴 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 = � 𝐵𝐵
∆𝐴𝐴𝑇𝑇𝑇𝑇
�  𝑇𝑇 𝐷𝐷 
ALT activity = nmol/min/ml = mU/ml 
Where: 
B = Amount of pyruvate from standard curve 
ΔT = reaction time 
V = original sample volume added to the reaction well in ml 
D = sample dilution factor 
Unit definition: 1 unit ALT = the amount of ALT that generates 1.0 µmol of pyruvate per min at 
37 ˚C. 
Protocol 2: Albumin Rat ELISA Kit 
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The Albumin Rat ELISA Kit albumin (Abcam, ab108790, SA) was used to measure Albumin in 
the plasma. The ELISA was executed according to the manufacturer’s instructions.  
Reagent preparation 
1. Thaw the plasma on ice
2. Equilibrate all the reagents to room temperature (18-25˚C)
3. Dilute the 10X diluent N concentrate 10-fold with distilled water to produce a 1X diluent.
4. Dilute the 20X wash buffer concentrate 20-fold with distilled water abd mix gently and
thoroughly.
5. Add 4.5 ml of the 1X diluent N to the lyophilized biotinylated albumin vial to generate a
working solution. Allow the vial to sit for 10 minutes with gentle agitation prior to use.
Spin down the 100X streptavidin-peroxidase conjugate (SP conjugate) briefly and dilute
the desired amount of the conjugate 100-fold with 1X diluent N.
6. Chromogen substrate ready to use as supplied
7. Albumin standard ready to use as supplied
8. Stop solution ready to use as supplied
9. Albumin Microplate 96 wells ready to use as supplied
10. Sealing tape ready to use as supplied
Standard preparation 
1. Reconstitute the albumin standard vial to prepare 50 µg/ml of Albumin standard #1:
a. Consult the albumin standard vial to determine the mass of protein in the vial.
b. Calculate the appropriate volume of 1X diluent to add to the albumin standard vial
to produce a concentration of 50 µg/ml, by using the following equation:
�
𝐶𝐶𝑆𝑆
𝐶𝐶𝐹𝐹
�  𝑇𝑇 1,000 = 𝑇𝑇𝐷𝐷 
Where: 
 CS = starting mass of albumin standard (see vial label) (µg) 
CF = The 50 µg/ml albumin standard #1 final required concentration 
VD = Required volume of 1X Diluent N for reconstitution 
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c. Briefly spin down your albumin standard vial to collect the contents at the bottom
of the tube.
d. Reconstitute the albumin standard vial with the appropriate volume of 1X diluent.
e. Mix gently and thoroughly.
f. Allow to sit for 10 minutes before use
2. Label seven tubes #2-8
3. Add 120 µl of 1X diluent N to tube #2-8
4. To prepare standard #2, add 120 µl of the standard #1 to tube #2 and mix gently
5. To prepare standard #3, add 120 µl of standard #2 into tube #3 and mix gently
6. Prepare subsequent serial dilutions using the table below as a guide:
Standard # Volume to 
dilute (µl) 
Volume 
Diluent N 
(µl) 
Total 
volume 
(µl) 
Starting 
concentration 
(µg/ml) 
Final 
Concentration 
 (µg/ml) 
1 Step 1 50 
2 120 120 240 50.00 25 
3 120 120 240 25.00 12.50 
4 120 120 240 12.50 6.250 
5 120 120 240 6.250 3.125 
6 120 120 240 3.125 1.563 
7 120 120 240 1.563 0.781 
8 120 120 0.00 0 
Assay procedure 
1. Prepare all the reagents as instructed and equilibrate to room temperature prior to use. The
assay is performed at room temperature (18 - 25˚C).
2. Remove excess microplate strips from the plate frame and return them immediately to the
foil pouch with the desiccant inside.
3. Add 25 µl of Albumin standard or sample per well and immediately add 25 µl of
biotinylated albumin protein to each well, on top of the standard or sample. The standard
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should be tested in triplicate and the sample in duplicate/triplicate. Gently ta plate to 
ensure thorough mixing and break any bubbles that may have formed. Cover the wells 
with the sealing tape and incubate for 1 hour.  Start the hour after the last sample addition.  
4. Wash five times with 200 µl of 1X wash buffer manually. Invert the plate each time and
decant the contents by tapping it 4-5 times on absorbent paper towel to completely
remove the liquid.
5. Add 50 µl of 1X SP conjugate to each well. Gently tap plate to thoroughly coat wells.
Break any bubbles that may have formed. Cover wells with sealing tape and incubate for
30 minutes.  Turn on the microplate reader and setup the program in advance.
6. Wash microplate as described above
7. Add 50 µl of chromogen substrate per well. Gently tap plate to thoroughly coat the wells.
Break any bubbles that may have formed. Incubate for 10 minutes or until the optimal
blue colour density has formed.
8. Add 50 µl of stop solution to each well. The colour will change from blue to yellow.
Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
9. Read the absorbance on a microplate reader immediately at a wavelength of 450 nm.
Calculations to determine concentration of Albumin in the plasma 
1. Calculate the mean value of the triplicate/duplicate absorbance readings for each standard
and sample.
2. Generate a standard curve by plotting the graph using the standard concentrations on the
x-axis and the corresponding mean absorbance on the y-axis.
3. The best fit line can be determined by regression analysis issuing log-log or four
parameter logistic curve-fit.
4. Determine the unknown sample concentration from the standard curve and multiply the
value by the dilution factor.
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Appendix E 
________________________________________________________________ 
Histological procedure for staining paraffin embedded tissue 
Protocol 1: Preservation and sectioning of tissue stored in 4% formaldehyde 
The entire process of making a histological slide can broadly be divided into six main steps, 
which are: (1) Tissue collection and fixation (2) Tissue processing (3) Embedding (4) Sectioning 
(5) Staining and (6) Mounting of the tissue. Each one of these steps has an important function and 
mistakes at any level could interfere with results obtained during microscopic evaluation of the 
slide.  
Tissue collection and fixation. 
Tissue should be harvested from the animal before or immediately after death. This is to 
minimize tissue degradation due to putrefaction and autolysis that occurs as soon as tissue is 
removed from the body or after death of the animal. For fixation of samples; place in a specimen 
tube with 4& formaldehyde solution for a minimum of 48 hours. The fixation stops tissue 
degradation and ensures that tissue structure is not lost.  
Tissue processing. 
Section tissues into smaller pieces to be placed into embedding cassettes for tissue processing. 
The tissue processing procedure are divided into 3 steps: dehydration with a series of alcohols, 
clearing with xylene and infiltration with paraffin wax. Dehydration with a series of different 
alcohol concentrations ensures that all water in the tissue are removed. Due to alcohol not mixing 
with water, the clearing step replaces the alcohol with xylene, which can mix and be replaced 
with paraffin wax during the infiltration steps. Infiltration with paraffin wax allows for further 
preservation and sectioning into microscopically thin sections once embedded. The tissue was 
processed with an automated processor (Sakura Finetechnical Co. Ltd, Tissue Tek II 4634, Japan) 
and Paraplast wax (Sigma-Aldrich, A6330-4LB, SA) was used for infiltration. The processing 
protocol is indicated in table 1 below. 
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Table 1: automated processing protocol 
Step # Solution Time (min) 
1 10% formalin 30 
2 70% Ethanol 30 
3 96% Ethanol 30 
4 96% Ethanol 30 
5 99.9% Ethanol 30 
6 99.9% Ethanol 30 
7 99.9% Ethanol 30 
8 Xylene 30 
9 Xylene 30 
10 Paraffin wax 60 
11 Paraffin wax 60 
12 Paraffin wax 60 
Steps 1-9 is completed at room temperature and steps 10-12 at 60 °C. 
Embedding. 
Place the processed tissue into a metal embedding mould with the appropriate orientation as this 
will determine the plane in which tissues are sectioned. Fill the mould with melted paraffin wax 
and immediately place a cassette on top of the mould.   This assembly is then placed on an iced 
surface to allow the wax to set. After the wax has set the tissue blocks were kept at 20-25°C 
(room temperature).  When embedding tissue, care should be taken to prevent formation of air 
bubbles in the in the wax, in and around the tissue. Such bubbles make sectioning difficult and 
may cause holes in the tissue section.  
Sectioning. 
Two hours prior to sectioning, place the tissue blocks in a freezer to cool. Trim and section the 
tissue block using a Leica RM 2125 RT microtome to obtain uniform 5µm sections. Place the 
sections into water at a temperature of approximately 40°C. This allows the tissue to stretch out 
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before being mounted onto a glass slide. Tissue should be picked up from the water bath with a 
glass slide at an angle, to prevent the formation of bubbles between the tissue and the glass slide, 
which will interfere with staining. During the process of sectioning, it is important to ensure that 
the blade of the microtome is does not become blunt, as this can cause artefacts. Tissue sections 
must be carefully moved from the microtome to the water bath. As sections are very thin they 
might tare or fold during this process disrupting tissue structure. Monitor the temperature of the 
water bath because a too high temperature causes tissue to disintegrate before it could be picked 
up with a glass slide. 
Protocol 2: Haematoxylin and Eosin (H&E) Staining. 
The standard H&E staining method, does not stain specific structures or differentiate between 
different cells within tissue, but allows for the visualization of all the cells that make up a tissue. 
Haematoxylin and eosin are two different dyes; haematoxylin being basic and staining acidic 
components of a cells, while eosin is acidic and stains basic cellular components 2. When animal 
cells are stained with H&E, the nucleus of the cell is stained blue by haematoxylin and the 
cytoplasm is stained pink by eosin. Sections stained with H&E allow for the evaluation of gross 
morphological characterization of tissue. In some cases, different cell types may be apparent if 
some cells stain lighter than others.  
Place slides in an incubator to melt the wax off the tissue. Liver tissue were stained with 
haematoxylin and eosin with an autostainer (Leica Auto Stainer XL).  Automation of the staining 
procedure, allows for replication of the procedure without human error or variation. The 
haematoxylin solution should be filtered before each run and eosin solutions must be correctly 
prepared to ensure correct and optimal staining. H&E staining protocol is shown in Table 3. The 
autostainer includes steps to deparaffinise, rehydrate and clear the tissue, so that the slide may 
eventually be permanently mounted. 
Table 2: H&E staining protocol 
Step # Solution Time (min) Repetitions 
1 Oven 60°C 2 min X1 
2 Xylene 5 min X2 
3 Ethanol 99% 2 min X2 
4 Ethanol 96% 2 min X1 
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5 Ethanol 70% 2 min X1 
6 Tap water 2 min X1 
7 Haematoxylin 8 min X1 
8 Running water 5 min X1 
9 Eosin 4 min X1 
10 Running water 1 min X1 
11 Ethanol 70% 30 sec X1 
12 Ethanol 96% 30 sec X2 
13 Ethanol 99% 30 sec X1 
14 Xylene 1 min X1 
Mounting 
Cover the tissue on the slide with DPX mounting media and place a cover slip ontop. Leave to 
dry for 48 hours.  
The mounting solution should not be stirred too much and the cover slip placed on the slide at an 
angle, this prevents bubbles from forming. Bubbles will interfere with the visualisation of the 
tissue under the microscope and if they do occur they should be carefully pushed out by pushing 
down on the coverslip with a pincet. Mounting of the slides completes the histological slide 
preparation process. Slides can now be viewed under the microscope and images captured for 
morphometric analysis. 
Quantification of haematoxylin and Eosin images.  
Hydropic changes were observed in the H&E staining of the hepatic tissue which are the first 
structural changes that occur in response to liver damage. They are the formation of non-uniform 
fluid filled sacs in the cytoplasm of the hepatocytes and was semi-quantified by constructing a 
grading system (Table 3) where the percentage hydropic changes per 10x image of 4 lobes per rat 
was determined. An average was then calculated and grades assigned per treatment group.  
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Table 3: Grading system for ballooning 
Percentage (%) 
change 
0 > 25 25 > 50 50 > 75 75 > 100 
Grade Minimal Mild Moderate Severe 
The percentage (%) hydropic change was determined by dividing one 10x image per lobe into 
100 blocks (see below). The presence of hydropic change within hepatocytes in each block was 
then determined, and a percentage calculated based on the amount of blocks that had hepatocytes 
with the hydropic changes. The presence of central veins and portal triads that stretched over an 
entire block were excluded from the quantification. Those with hydropic received Yes and those 
with healthy hepatocytes, received NO. 
No = 13 blocks  Yes = 85  Blocks excluded = 2, thus, total blocks = 98 
Yes Yes Yes Yes Yes Yes Yes No Yes Yes 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Yes Yes Yes Yes Yes Yes No No Yes Yes 
Yes Yes Yes Yes Yes Yes Yes No Yes Yes 
Yes Yes Yes Yes Yes Yes Yes Yes Yes No 
No No Yes Yes Yes Yes Yes Yes Yes 
No Yes Yes Yes Yes Yes Yes No Yes 
No Yes Yes Yes Yes Yes Yes Yes Yes Yes 
No Yes Yes Yes No Yes Yes Yes Yes Yes 
No Yes Yes Yes No Yes Yes Yes Yes Yes 
Excluded 
Excluded 
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 % hydropic change = 85/98*100 = 86.7% 
Protocol 3: Gordon’s and Sweets staining for reticulin 
Principle: 
Reticulin fibres have little natural affinity for silver solutions. Therefore, they need to be treated 
with potassium permanganate to produce sensitized sites on the fibres where silver deposition can 
be initiated. The silver is a in a form readily able to precipitate as metallic silver (diamine silver 
solution). The optimal pH for maximum uptake of silver ions is 9.0. A reducing agent, formalin, 
causes deposition of silver in the form of metal. Any excess silver in the unprecipitated state is 
removed by hypo. Gold Chloride treatment renders the preparation permanent and produces a 
neutral black color of high intensity.  
Technical Points: 
• Make the silver solution each time. Ammoniacal solutions can be explosive when allowed
to dry. Immediately after use neutralise the silver solution with saturated sodium chloride
and discard.
• Clean glassware used to prepare the silver solution with glassware cleaning solution. .
was thoroughly before use with tap water and use distilled water for the final rinse.
• It is important not to over dissolve the precipitate at any stage as this will result in a
decrease in sensitivity.
• Omit step 12 for untoned retics. (i.e, liver specimens)
• Omit step 16 for haematology trephines.
Method: 
1. Deparafinise sections with Xylene then take through alcohols to tap water:
• Xylene, Xylene, 99% alcohol, 99%, 96%, 96%, 70% and lastly, tap water.
• 5 Minutes in each solution
2. Oxidise in acidified potassium permanganate for 3 minutes
3. Rinse in distilled water
4. Decolourise with 2% oxalic acid for 1 minute.
5. Rinse in distilled water
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
96 
6. Mordant in 4% iron alum for 10 minutes (upright 45°-degree angle)
7. Rinse in distilled water
8. Impregnate in ammoniacal silvers solution for 11 seconds
9. Rinse quickly in distilled water
10. Immediately reduce with 10% aqueous formalin solution for 2 minutes
11. Wash in running tap water for 2 minutes
12. Tone in 0.2% Gold Chloride for 2 minutes (Omit this step for liver specimens).
13. Rinse in distilled water
14. Fix with 2% aqueous sodium thiophosphate (hypo) for 2 minutes
15. Wash in tap water for 2 minutes
16. Counterstain with neutral red for 2 minutes (Reggie alternatively uses the light green stain
– dip slides in solution briefly)
17. Dehydrate (through the alcohol solutions starting at 70% for 5 minutes each and then in
xylene for 1 min each) clear and mount.
Reticulin fibers = Black Nuclei = Red 
Reagent formulae: 
1. Acidified Potassium permanganate XE “Potassium permanganate acidified 37”
a. 0.5% Potassium permanganate ___95 ml (0. 5 dissolved in 100 ml dH2O)
b. 3% Sulphuric acid_______________3 ml (1.5 in 50)
2. Silver solution
a. To 5 ml of 10% aqueous silver nitrate add strong ammonia drop by drop until the
precipitate which firsts forms is just dissolved. Add 5 ml of 3% sodium hydroxide
then add strong ammonia drop by drop until the resulting precipitate is almost
compltetely dissolved.  Make up to 50 ml with dH2O and pour in a clean coplin
jar.
3. 2% aqueous Oxalic acid
a. Oxalic acid (analytical)____ 2g
b. Distilled water ___100 ml
4. 4% aqueous iron alum
a. Iron alum (ferric ammonium sulphate) ___ 4g
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b. Distilled water___100 ml
5. 10% formalin
a. Formaldehyde (Ajax, 37 40g/L) ___ 10 ml
b. Distilled water____ 100 ml
6. 0.2% gold chloride
a. Gold Chloride (Sodium tetrachloroaurate, BDH) ___ 2g
b. Distilled water___100 ml
7. 2% sodium thiosulphate (hypo)
a. Sodium thiosulphate ___2g
b. Distilled water___100 ml
8. Neutral red stain – acidified
a. Neutral red (Cl 500400 ___ 1.0 g
b. Distilled water___100 ml
c. Acetic acid ___1.0 ml
Protocol 4: Periodic acid Schiff staining for glycogen 
This method is used for the detection of glycogen in tissues such as the liver, cardiac and skeletal 
muscle in formalin fixed, paraffin-embedded tissue sections, and may be used for frozen sections 
as well. The glycogen, mucin and fungi will be stained purple and the nuclei will be stained blue.  
Fixation: 10% formalin 
Section: paraffin sections at 5 µm 
Solutions and reagents: 
1% periodic acid solution: 
1 g periodic acid dissolved in 100 ml distilled water. 
Schiff reagent: 
Schiff’s aldehyde reagent (Merck Millipore, 109034, SA). 
Test for Schiff reagent: pour 10 ml of 37% formalin into a watch glass. To this add a few drops 
of the Schiff reagent to be tested. A good Schiff reagent will rapidly turn a red-purple colour. A 
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deteriorating Schiff reagent will give a delayed reaction and the colour produced will be a deep 
blue – purple.  
Mayer’s haematoxylin solution: 
Used as purchased from company (Merck Millipore, SAAR2822001LC, SA). 
Procedure: 
1. Deparafinize and hydrate to water by placing in the following solutions for 5 min each:
a. Xylene
b. Xylene
c. 99% Alcohol
d. 99% Alcohol
e. 96% Alcohol
f. 96% Alcohol
g. 70% Alcohol
h. Tap water – may leave slides in water overnight.
2. Oxidize in 1% Periodic acid solution for 5 min
3. Rinse in distilled water
4. Place in Schiff reagent for 15 min (sections become light pink colour  during this step)
5. Wash in lukewarm water for 5 min (Immediately sections turn dark pink colour)
6. Counterstain in Mayer’s haematoxylin for 1 min
7. Wash in tap water for 5 min
8. Dehydrate by dipping slides in the alcohol solutions 5 times each and 1 min each in the
xylene:
a. 70% Alcohol
b. 96% Alcohol
c. 96% Alcohol
d. 99% Alcohol
e. 99% Alcohol
f. Xylene
g. Xylene
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9. Add coverslip using a synthetic mounting medium (slides should not dry out thus leave
slides in xylene while mounting)
Results: 
Glycogen, mucin and some basement membranes – red/purple 
Fungi - red/purple 
Background - Blue 
Protocol 4: Masson’s trichrome for fibrosis 
The Masson’s trichrome stain detects type I and III collagen deposition indicative of scarring 
(fibrosis).  
Staining solutions 
1. Mayer’s haematoxylin solution
2. Acetic Acid Water
a. Glacial acetic acid             -2ml 
b. Distilled water      -1000ml 
3. Masson Fuchson Ponceau-Orange G
a. Stock solution – Ponceau (2R) de xylidine  -2g
b. Acid fuchsin     -1g
c. Orange G       -2g
d. Acetic acid water  0.2%     -300ml
4. Working solution
a. No . 3 (MFPOG)      -10ml 
b. Acetic acid water 0.2%       -90ml 
5. Light Green Solution
a. Light green    -0.1g
b. Acetic acid water 0.2      -100ml 
6. Phosphotungstic acid 5%
a. Phosphotungstic acid     -5g
b. Distilled  water      -100ml  
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Method 
1. Deparaffinize sections and bring to water.
2. Rinse in distilled water.
3. Stain in haematoxylin for 5min.
4. Run in tape for 3min till dark blue and rinse in distilled water.
5. Stain the sections in filtered working solution of fuchsin ponceau-orangeG for 5-30min
(15 minutes for this study)
6. Rinse in acetic acid water.
7. Mordant in 5% phosphotungtic acid solution for 5min.
8. Rinse in acetic acid water for 1min to eliminate the phosphotungstic acid and differentiate
the colour tones.
9. Stain in light green solution for 5-20 min. (20)
10. Treat with acetic acid water for 5min.
11. Dehydrate through alcohols.
12. Clear in xylene and mount in DPX mounting medium.
Result 
Nuclei               - black 
Cyttoplasm      - red 
Collagen           - green 
Mucin               - green 
Erythrocytes    - yellow to orange 
Protocol 5: Immunohistochemical staining procedure and manual rehydration (ALT) 
Follow steps of 1-4 of basic histological procedure: 
1) Tissue collection and fixation
2) Tissue processing
3) Embedding
4) Sectioning
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Alanine aminotransaminase (ALT) (Santa Cruz biotechnology, Sc-271861, SA) was probed for by 
IHC using the Bond-MaxTM Autostainer (Leica Biosystems, Germany) and the BondTM Polymer 
Refine detection kit (Leica Biosystems, DS9800, Germany). Table 3 below indicates the 
automated staining procedure 
Table 3: Automated Immunohistochemical double staining procedure 
Step # Solution Incubation time 
(min) 
Temperature (°C) 
1 Bond wash solution 0 72 
2 Bond wash solution 0 72 
3 Bond wash solution 0 Room temperature 
4 Alcohol 0 Room temperature 
5 Alcohol 0 Room temperature 
6 Alcohol 0 Room temperature 
7 Bond wash solution 0 Room temperature 
8 Bond wash solution 0 Room temperature 
9 Bond wash solution 0 Room temperature 
10 Bond ER solution 1 0 Room temperature 
11 Bond ER solution 1 0 Room temperature 
12 Bond ER solution 1 20 100 
13 Bond ER solution 1 12 Room temperature 
14 Bond wash solution 0 35 
15 Bond wash solution 0 35 
16 Bond wash solution 0 35 
17 Bond wash solution 3 Room temperature 
18 Peroxide block 5 Room temperature 
19 Bond wash solution 0 Room temperature 
20 Bond wash solution 0 Room temperature 
21 Bond wash solution 0 Room temperature 
22 Primary antibody 30 Room temperature 
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23 Bond wash solution 0 Room temperature 
24 Bond wash solution 0 Room temperature 
25 Bond wash solution 0 Room temperature 
26 Post primary 8 Room temperature 
27 Bond wash solution 2 Room temperature 
28 Bond wash solution 2 Room temperature 
29 Bond wash solution 2 Room temperature 
30 Polymer 8 Room temperature 
31 Bond wash solution 2 Room temperature 
32 Bond wash solution 2 Room temperature 
33 Deionized water 0 Room temperature 
34 Mixed DAB refine 0 Room temperature 
35 Mixed DAB refine 10 Room temperature 
36 Deionized water 0 Room temperature 
37 Deionized water 0 Room temperature 
38 Deionized water 0 Room temperature 
39 Haemotoxylin 5 Room temperature 
40 Deionized water 0 Room temperature 
41 Bond wash solution 0 Room temperature 
42 Deionized water 0 Room temperature 
43 Primary antibody 15 Room temperature 
44 Bond wash solution 0 Room temperature 
45 Bond wash solution 0 Room temperature 
46 Bond wash solution 0 Room temperature 
47 Polymer AP 20 Room temperature 
48 Bond wash solution 2 Room temperature 
49 Bond wash solution 2 Room temperature 
50 Bond wash solution 2 Room temperature 
51 Polymer AP 30 Room temperature 
52 Bond wash solution 2 Room temperature 
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53 Bond wash solution 2 Room temperature 
54 Bond wash solution 5 Room temperature 
55 Bond wash solution 2 Room temperature 
56 Bond wash solution 0 Room temperature 
57 Deionized water 0 Room temperature 
58 Mixed red refine 10 Room temperature 
59 Mixed red refine 5 Room temperature 
60 Deionized water 0 Room temperature 
61 Deionized water 0 Room temperature 
62 Deionized water 0 Room temperature 
63 Haematoxylin 5 Room temperature 
64 Deionized water 0 Room temperature 
65 Bond wash solution 0 Room temperature 
66 Deionized water 0 Room temperature 
The primary antibody used were: Mouse anti-rat alanine transaminase primary antibody at a 
1:1000 dilution. Purchased from Santa Cruz biotechnology cat. # sc - 271861 
Table 4: Manual rehydration 
Step # Solution Time Repetitions 
1 Ethanol 70% 5 dips 1 
2 Ethanol 96% 5 dips 1 
3 Ethanol 99% 5 dips 1 
4 Xylene 1 min 2 
Cover the tissue on the slide with PDX mounting media and place a cover slip ontop. Leave to 
dry for 48 hours.  The mounting solution should not be stirred too much and the cover slip placed 
on the slide at an angle, this prevents bubbles from forming. Bubbles will interfere with the 
visualisation of the tissue under the microscope and if they do occur they should be carefully 
pushed out by pushing down on the coverslip with a pincet. Mounting of the slides completes the 
histological slide preparation process. Slides can now be viewed under the microscope and 
images captured for morphometric analysis. 
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Appendix F 
________________________________________________________________ 
Oil red O staining of frozen tissue 
1. Frozen liver tissue was placed in liquid nitrogen and sectioned into 7 µm thick sections
with a cryostat (Leica CM 3050 S Research Cryostat, Leica Biosystems) which was kept
at a temperature of -12 ˚C.
2. The sections was then placed onto positively charged Histobond microscope slides
(Lasec, GLAS2S13M0810401).
3. The sections were left to defrost
4. Followed by placing in the oil red O staining solution (Sigma-Aldrich, O1391, SA) for 20
minutes.
5. The slides was briefly washed in washed in cold tap water to remove excess staining
solution.
6. The sections were then counterstained with 50% crystal violet (Sigma-Aldrich, V5265)
for 1 minute.
7. Wash slides in cold tap water for 3 min
8. Leave the sections to air dry
9. Place aqueous mounting media (Sigma-Aldrich, G 0918) onto the sections with a
coverslip. 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
105 
Appendix G 
________________________________________________________________ 
Protocols for oxidative stress analysis 
Protocol 1: Tissue preparation for TBARS, conjugated dienes and glutathione assays. 
Buffer preparation 
1. Phosphate buffer 75 mM, pH 7.4
a. Weigh 1.035 g sodium di-hydrogen orthophosphate-1-hydrate in 100 ml distilled
water and mix until dissolved.
b. Weigh 1.335 g di-sodium hydrogen orthophosphate dehydrate in 100 ml distilled
water and mix until dissolved.
c. Mix 18 ml of the first solution, sodium di-hydrogen orthophosphate-1-hydrate,
with 82 ml of the second solution, di-sodium hydrogen orthophosphate dehydrate.
d. Adjust the pH of the buffer to 7.4
e. Store at 4˚C
2. Phosphate buffer 75 mM, pH 7.4 with M2VP
a. Prepare the M2VP by dissolving 8 mg of M2VP in 0.1 M HCl.
b. For every 990 µl of phosphate buffer add 10 µl of M2VP.  Prepare a stock solution
and work from there
Tissue preparation  
1. Thaw frozen liver tissue on ice.
2. Weigh ±100 mg of tissue off and place in a pre-chilled 2ml Eppendorf tube. Weigh two
separate pieces off per rat.
3. For the one piece: add phosphate buffer (75 mM, pH 7.4), a ratio of 1/10 (w/v) to the
tissue. Example: 100 mg of liver tissue add 1000 µl phosphate buffer add for 96 mg of
tissue add 960 µl of the phosphate buffer.  This will be used for TBARS, Conjugated
Dienes and Glutathione (to measure GSH) assay
4. For the other piece: Add the stock solution of phosphate buffer with M2VP also at a ratio
of 1/10 (w/v) as described above in 3.  This will be used for the glutathione assay (to
measure GSSG)
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5. Homogenize the tissue in the buffer on ice, with a dense homogenizer (Kinematica,
POLYTRON® PT 2100 Homogenizer Switzerland) at 22 000 rpm for ±20 seconds until a
lysate forms.
6. Sonicate at 10 A for 10 seconds (Qsonica, Misonix Sonicator S-400, USA).
7. Allow the froth to settle for 30 minutes.
8. Centrifuge (Labnet, Spectrafuge 16M, USA)  at 12 000 rpm at 4 ˚C for 10 minutes
9. Remove the supernatant and place in a pre-chilled Eppendorf tube. Discard the pellet.
10. Store at – 80 ˚C.
Protocol 2: Conjugated Dienes Assay 
1. Use the lysate prepared by only adding the Phosphate buffer (75 mM, pH 7.2), for this
assay.
2. Prepare a solution of 2:1 methanol to chloroform by adding, 33 ml methanol to 67 ml
chloroform.
3. Place 100 µl of sample into a 2 ml Eppendorf tube
4. Add 500 µl of the 2:1 chloroform to methanol solution to each sample
5. Invert the Eppendorf tube to mix
6. Centrifuge at 14 000 rpm for 1 minute
a. Two layers form, the top layer is a protein layer and the bottom liquid layer is the
conjugated dienes dissolved in the solution.
b. Pipette 200 µl of the bottom into a new labelled Eppendorf tube. Take care not to
remove the protein layer as well.
7. Leave the new Eppendorf tube with 200 µl of the sample, at 4˚C overnight over a flow of
nitrogen (in the fridge) for the solution to evaporate and the conjugated dienes to stay
behind in the tube. Do not close the lids of the Eppendorf tubes.
8. The following day, the solution will have evaporated.
9. Add 1000 µl of cyclohexane to each Eppendorf tube
10. Vortex for ±20 seconds
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11. Transfer 300 µl of the sample and the cyclohexane as the blank to the wells of clear 96
well UVplate (Thermoscientific Inc, Microplate Uv Flat Bttm CS40, Netherlands). Test
blank and samples in triplicate.
Measure the absorbance (Thermo Electron Corporation, Multiskan spectrum, Finland) at 230 nm 
immediately 
Protocol 3: TBARS assay  
Materials and reagents required: 
1. Clear 96 well plate
2. A heating water bath set at 90 ˚C
3. Vortex
4. Centrifuge
5. Pipettes
6. O.11M Thiobarturic acid (TBA)
7. 0.2M Orthophosphoric acid (OPA)
8. 4mM  3,5-Di-tert-4-butylhydroxytoluene (BHT)
Assay procedure  
1. Use the lysate prepared by only adding the Phosphate buffer (75 mM, pH 7.2), for this
assay.
2. Add 50 µl of sample into a 2 ml Eppendorf tube.
3. Add 6.25 µl 4Mm BHT to each sample
4. Add 50 µl of ortho-phosphoric acid to each sample
5. Vortex to mix
6. Add 6.25 µl 0.11M TBA reagent to each sample
7. Vortex to mix
8. Punch a hole in the lid of each Eppendorf tube
9. Heat at 90 ˚C in the water bath for 45 minutes. Be strict with time and temperature for
every repeat. All the samples should be placed into and removed out of the water bath
simultaneously.  The heat catalyse the reaction.
10. To stop the reaction, place samples in an ice bath for 2 minutes (or until needed).
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11. Add 1000 µl of Butanol (100%) to each sample and invert the Eppendorf tube to mix. Use
your finger to cover the hole in the lid.
12. Centrifuge at 14 000 rpm for 1 minute at room temperature.
13. Transfer 300 µl of the top layer to the wells of clear 96 well plate. Use the butanol as the
blank. Test samples in triplicate.
14. Measure the absorbance (Thermo Electron Corporation, Multiskan spectrum, Finland)
immediately at 532 nm.
Protocol 4: Glutathione assay 
This assay consists of two parts: measurement of reduced glutathione (GSH) and measurement of 
oxidized glutathione (GSSG). The assay procedure remains the same but the samples are 
prepared differently.  
To measure GSH use the lysate prepared by only adding the phosphate buffer (75 mM,pH 7.4) 
and for the measurement of GSSG, use the lysate prepared by adding the phosphate buffer with 
M2VP solution.  
Materials and reagents required:  
1. Phosphate buffer (75 mM, pH 7.4)
2. I vial reduced nicotinamide adenine dinucleotide phosphate (NADPH) (Sigma-Aldrich,
N6785) (1 mM). Add 12 ml in phosphate buffer (75 mM, pH 7.4) to 1 vial NADPH.
3. 5,5'-dithiobis-(2-nitrobenzoic acid (DTNB) (Sigma-Aldrich, D21820) 30 mM in
phosphate buffer (75 mM, pH 7.4)
4. Standard solution (GSH - 3µm) (GSSG – 1.5 µM) in phosphate buffer (75 mM, pH 7.4)
5. Glutathione reductase (Sigma Aldrich, G3664, SA) [16 µl in 984 µl phosphate buffer (75
mM, pH 7.4)]
Assay procedure: 
1. Prepare a standard curve and a dilution series of your samples to determine at what
dilution the samples should be at to fall within the standard curve.
2. Prepare the standard curve as follows:
Blank 1 2 3 4 5 
GSH (µl) 0 167 333 500 667 833 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
109 
Phosphate 
buffer (75 mM, 
pH 7.4) 
1000 833 667 500 333 167 
3. A standard should be tested prepared for each plate and test. Add 50 µl of standards and
samples to the wells of a clear 96 well plate.
4. Add 50 µl of the DTNB to each well using a multichannel.
5. Add 50 µl of the glutathione reductase using a multichannel.
6. Add 50 µl NADPH to each well as quickly as possible (30 seconds max)
7. Measure absorbance at 412 nm every 30 seconds for 3 minutes.
8. Use linear slope of the standards to calculate concentration of samples
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Appendix H 
________________________________________________________________ 
Protocol for western blotting 
Protocol 1: Reagent preparation for western blot 
Modified Radio immunoprecipitation assay buffer (RIPA) buffer 
1. Dissolve 790 mg Tris base and 900 mg Sodium Chloride (NaCl) in 75 ml distilled water.
Adjust the pH of the solution to 7.4 using Hydrochloric acid (HCl).
2. Add 10 ml of 10% triton x100 to the solution
3. Add 2. 5 ml of 10% Na-deoxycholate and stir until the solution is clear
4. Add 1 ml of 100 mM EDTA to the solution followed by adjusting the volume of the
solution to 100 ml with distilled water
5. Aliquot the buffer in 10 ml amounts and store at 4 ˚C until day of use.
6. On the day of use add the following:
a. PMSF: 10 µl/ml RIPA buffer (half-life 30 minutes)
b. 200 mM NaF: 5 µl/ml RIPA buffer
c. Na2VO3: 5 µl/ml RIPA buffer
d. Phosphatase and protease inhibitor cocktail: 42 µl/1ml RIPA buffer
10X TBS 
1. Dissolve 24.2 g Tris and 80 NaCl in 600 ml distilled water.
2. Adjust pH to 7.6 with HCl
3. Make up to 1000 ml with distilled water
1X TBS-T 
1. Mix 100 ml of the 10X TBS with 900 ml distilled water.
2. Add 1 ml Tween
3. Mix well do not adjust pH
Laemmli’s loading buffer  
First prepare stock solution A. 
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1. 38 ml distilled water
2. Add 10 ml of 0.5 M Tris (pH 6.8)
3. Add 8 ml glycerol
4. 16 ml 10% Sodium dodecyl sulphate (SDS)
5. 4 ml of 0.05% Bromophenol blue
On the day of use prepare a working solution of Laemmli’s loading buffer by adding mercapto-
ethanol: for every 850 µl Solution A, add 150 µl mercapto-ethanol.  
Running buffer 
Dilute 10X running buffer to 1X running buffer: 
1. 100 ml 10X running buffer with 900 ml distilled water.
2. Mix well
5% Blocking buffer 
1. 5 ml Parmalat fat free milk dissolved in 95 ml 1X TBS-T
2. Mix well
3. Use 50 ml of this solution per membrane
Protocol 2: Sample preparation 
1. Frozen liver tissue was used for Western blot analysis. Thaw liver tissue on ice.
2. Add 300 µl of the modified RIPA buffer to each 2 ml Eppendorf tube with tissue.
3. On ice, homogenize the tissue with a dense homogenizer (Kinematica, POLYTRON® PT
2100 Homogenizer Switzerland) at 22 000 rpm for ±20 seconds.
4. Place samples back on ice and allow froth to settle for 60 minutes.
5. Centrifuge at 14 000 rpm at 4˚C for 60 minutes
a. 3 layers form: a top fat layer, a middle protein layer and at the bottom, the pellet.
6. Remove the middle protein layer with a 23-gauge needle attached to a 1 ml syringe. Insert
the 23-gauge needle attached to a 1 ml syringe into the side, at the middle, of the
Eppendorf tube to remove the protein lysate.
7. Place the protein lysate into a pre-chilled 2 ml Eppendorf tube.
8. To ensure that the lysate is free of fat and cellular debris contaminants, centrifuge the
lysate again at 14 000 rpm at 4 ˚C for 40 minutes.
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9. Remove the protein lysate and discard the pellet.
Protein concentration determination 
The Direct Detect ™ Spectrometer (Merck Millipore, DDHW00010-WW, Germany) was used to 
determine the protein concentration within each lysate. This system measures the absorbance of 
amide bonds in protein chains using infrared quantitation thereby determines intrinsic 
components of every protein without relying on amino acid composition, dye binding properties 
and redox potential. 
1. Apply 2 µl of sample into positions 2-4 of the direct detect card. Position 1 is for the
blank. Use the modified RIPA buffer as the blank.
2. Insert the card vertically into the slot in the top of the sampling accessory with the card
notch facing towards the center of the instrument
3. The instrument will dry the sample and then take protein concentration measurements in
mg/ml.
Sample preparation for loading 
1. Determine the volume of lysate required to load 30 µg of protein into the wells by using
this equation:  (30x1000)
protein concentration (µg/ml)
2. Add the appropriate volume of lysate to 20 µl laemmli’s buffer.
3. Punch a hole in Eppendorf tube and boil at 95˚C for 5 minutes before loading into the
wells of the gel for electrophoresis.
Protocol 3: Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
1. Use the 1 mm glass plates and assemble to pour gels.
2. Prepare the 12% TGX stain-free™ FastCast™ acrylamide gels according to the
manufacturer’s instructions (Bio-Rad, 1610183, SA).
3. Use a Pasteur pipette to first pour the resolving gel into the assembled glass plates until
about 2 cm under the brim of the front plate, then immediately pour the stacking gel and
fill to the brim of the front plate.
4. Immediately insert the 10 well comb being careful not to form bubbles.
5. Allow gels to set for 40 minutes.
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6. Once the gels have set in the glass plates, remove the combs and lace in the U-shaped
adapter with the short plate facing inwards. This will form a center in the adapter called a
buffer dam. NB: two gels is required to form the buffer dam, if only running one gel, use
an insert called a buffer dam in the place of the second gel.
7. Place the assembly in a gel tank and fill the buffer dam with 1X running buffer.
8. Start loading samples and a protein marker into the wells using the gel loading tips.
9. Place the lid of the tank on top of the tank with the appropriate leads (black to black and
red to red) and connect to the power pack.
10. Run at 90 V until the blue frontline and the smallest standard of the protein marker
reaches the bottom of the gel.
11. Remove the gel from the gel plates and active the gels in the ChemiDoc™ XRS+ system
(Bio-Rad, USA).
12. Transfer onto a PVDF membrane. (Bio-Rad, Trans-Blot® Turbo™ ready-to-assemble
mini low fluorescent PVDF transfer kit, 1707274, USA)
a. Soak transfer stack in the transfer buffer supplied by transfer kit and prepared as
manufacturer indicates.
b. Place the PVDF membrane in 100% methanol for ±30 seconds and then in the
transfer buffer.
c. Assemble the transfer stack and membrane in the TransBlot® Turbo™ Transfer
System (Bio-Rad, USA) with the transfer stack placed down first, roll out any
bubbles or wrinkles that may have formed on the transfer stack and then place the
membrane on top.  NB: Do not roll the membrane.
d. After the gel have been activated, place the gel on top of the membrane. Roll out
any bubbles that may have formed.
e. Soak the second transfer stack in the transfer buffer and place on top of the gel.
Give a final role.
f. Place the lid of the cassette on top, and place the cassette into the TransBlot®
Turbo™ Transfer System (Bio-Rad, USA).
g. Transfer for 30 min at 25 V.
13. After transfer, take an image of the membrane in the ChemiDoc™ XRS+ system
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14. Place membrane in methanol for 30 seconds and then air dry the membrane.  This is to fix
the proteins into the membrane.  Wet the membrane in methanol again in order for it to
interact with hydrophilic solutions
15. Place the membrane in 5% blocking buffer for 60 minutes. Place on belly dancer at a very
low speed.
16. Wash membrane 3x 5mins in 1x TBS-T
17. Place membrane in primary antibody (see table 2.1 below for list of antibodies) on a
rotator overnight at 4 ˚C.
18. Wash membrane 3x 5mins in 1x TBS-T
19. Place membrane in secondary antibody for 60 minutes at room temperature on a rotator.
20. Wash membrane 3x 5mins in 1x TBS-T
21. Image in ChemiDoc™ XRS+ system. Place membrane in ChemiDoc™ XRS+ system and
cover the membrane in ECL (Bio-Rad, 1705061, USA). The bands are viculaized with the
Image Lab™ software and discrepancies in loading were corrected for by using total
protein normalization.
Table 2.1. List of primary and secondary antibodies used for Western blotting 
Primary Antibodies 
Name Size (kDa) Company (catalogue number) Dilution 
Cleaved Caspase-3 17, 19 Cell Signalling Technology (9662) 1:1 000 
Cleaved PARP 89 Cell Signalling Technology (5625) 1:1 000 
BiP 68 Cell Signalling Technology (3177) 1:1 000 
ATF4 48 
Cell Signalling Technology 
(11815) 1:1 000 
LC3 16, 18 Cell Signalling Technology (3868) 1:1 000 
p62 62 Cell Signalling Technology 
(5114) 
1:1 000 
ALT 48 
Santa Cruz Biotechnology (Sc-
271861) 
1:1 000 
Secondary Antibodies 
Anti-Rabbit IgG HRP-
linked 
0 Cell Signalling Technology (7074) 1:10 000 
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Abbreviations: PARP: Poly (ADP-ribose) polymerase, BiP: immunoglobulin heavy chain-binding 
protein, ATF4: Activating Transcription Factor 4, LC3: microtubule associated protein 1 light chain 3, 
ALT: alanine transaminase. 
Anti-mouse IgG HRP-
linked 
0 
Cell Signalling Technology 
(58802) 
1:10 000 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
116 
Appendix I 
________________________________________________________________ 
Reagents used  
Reagent Cat# Company 
,5-Di-tert-4-butylhydroxytoluene 
(BHT) 
442377 Sigma-Aldrich 
5,5'-dithiobis-(2-nitrobenzoic acid) 
(DTNB)  
D21820 Sigma-Aldrich 
Acetic acid water 600113 Radchem 
aqueous mounting media G 0918 Sigma-Aldrich, 
Butanol B7906 Sigma-Aldrich 
crystal violet V5265 Sigma-Aldrich 
Doxorubicin D5794 LKT Laboratories 
DPX mountant D0738NN00500 Associated Chemical 
Enterprises 
Formaldehyde 1.00496.5000 Merck Millipore, 
Ghrelin G2869 LKT Laboratories 
Glutathione reductase G3664 (Sigma Aldrich 
Iron alum 103776 Merck Millipore, 
Light green solution L1886 Sigma-Aldrich 
Mayer’s haematoxylin SAAR2822001LC Merck Millipore 
NADPH Sigma-Aldrich, N6785) Sigma-Aldrich N6785 
Oil red O staining solution O1391 Sigma-Aldrich 
Ortho-phosphoric acid (OPA) 1.00573.2500 Merck Millipore 
Oxalic acid 6153-56-6, Radchem 
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Paraplast® wax A6330-4LB Sigma-Aldrich, 
Potassium permanganate 109930 Merck Millipore, 
Sodium triphosphate T5041 Sigma-Aldrich 
Xylene 1086619190 Merck Millipore 
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Appendix J: 
________________________________________________________________ 
Permissions/copyright from journals for the use of figures  
Figure 1.2: Representation of the hepatic lobule and hepatic acinus and the arrangement of the 
hepatocytes and sinusoids. 
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Figure 1.3: Hepatic glycogen synthesis and breakdown.  
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Figure 1.4: Transamination and deamination reactions to metabolize amino acids  
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Figure 1.6: The Harber-Weiss and Fenton reaction. 
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Figure 1.4: Transamination and deamination reactions to metabolize amino acids  
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Figure 1.6: The Harber-Weiss and Fenton reaction. 
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